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ABSTRACT 
Influenza viruses cause annual epidemics and pandemics which have serious 
consequences for public health and global economy. The severity of infections with 
influenza viruses can vary from asymptomatic to life-threatening viral pneumonias 
frequently complicated by multi-organ failure and exacerbation of other underlying 
conditions. Currently, four licensed anti-influenza drugs are available for the prevention 
and treatment of influenza virus infections. However, resistance to the licensed 
antivirals develops rapidly. Therefore, there is a need for next-generation antiviral 
agents to combat influenza virus infections. 
Recent advances in understanding influenza virus-host interactions have revealed 
a number of host targets for potential antiviral interventions. In particular, basic cellular 
functions, metabolic and biosynthesis pathways as well as the signaling cascades 
essential for virus replication could be modulated by small-molecule inhibitors to block 
virus infection. Moreover, temporal inhibition of these host functions will be less likely 
to induce viral drug resistance. In addition, many of the inhibitors of cellular functions 
are already approved or in clinical development for other diseases. Drug repurposing 
will facilitate their introduction for treatment of viral infections, since the 
pharmacokinetics and toxicity profile of these drugs are already known. 
In this work, a library of small-molecule inhibitors targeting host factors and 
potentially interfering with influenza virus infection was built and screened. Inhibitors 
of vacuolar proton-ATPase (v-ATPase), Akt kinase, ribonucleotide reductase and the 
anti-apoptotic B-cell lymphoma-2 (Bcl-2) family proteins showed antiviral activity in 
vitro. However, ABT-263, an inhibitor of Bcl-2 family proteins, was ineffective in vivo. 
SaliPhe, an inhibitor of v-ATPase, was the most potent antiviral agent and it was 
effective against a broad range of influenza viruses and some other RNA viruses in 
vitro, and against a mouse adapted influenza strain in vivo. In order to overcome the low 
water solubility and high toxicity of SaliPhe, it was needed to optimize the drug’s 
bioavailability using a porous silicon particle-based delivery system prior to embarking 
on future clinical trials. The results presented in this study expand the understanding of 
influenza virus-host interactions, and are important for rational approaches of 
discovering new antiviral agents. 
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1. REVIEW OF THE LITERATURE 
1.1. Introduction 
Influenza viruses cause annual epidemics and pandemics with serious 
consequences for public health and global economy. During the annual epidemics, 
influenza viruses infect 5 – 15% of the human population resulting in 3 – 5 million 
cases of severe illness and 250,000 – 500,000 death each year all around the world 
(Shirey et al, 2013). In addition, occasionally strains to which humans are naïve appear 
and cause pandemic outbreaks. During the past 100 years, five pandemic influenza 
outbreaks have occurred: “Spanish flu” (H1N1) in 1918, “Asian flu” (H2N2) in 1957, 
“Hong Kong flu” (H3N2) in 1968, “Russian flu” (H1N1) 1977, and “swine flu” (H1N1) 
in 2009. In particular, the 1918 influenza pandemic affected almost 30% of the global 
population and is believed to have killed over 50 million people (Johnson & Mueller, 
2002). 
Influenza viruses usually invade the epithelial cells of the upper respiratory tract 
and cause acute respiratory disease. The typical influenza symptoms are fever, 
headaches, chills, nasal congestion, sore throat and body aches. However, the highly-
pathogenic influenza A (H5N1) virus infects the lower respiratory tract and causes viral 
pneumonia and acute respiratory distress syndrome. There may be multiple organ 
failure, caused by intense induction of proinflammatory cytokines. Recently, a new 
avian influenza A (H7N9) strain has been identified in China. The influenza H7N9 virus 
was characterized by rapidly progressive pneumonia, respiratory failure, acute 
respiratory distress syndrome, and fatal outcomes (39 deaths in 132 confirmed cases) 
(Li et al, 2013).  
1.2. Influenza A virus  
1.2.1. Structure and classification 
Influenza A viruses belong to the Orthomyxoviridae family which also includes 
the influenza B and C types. The influenza viruses differ in several ways, i.e. genome 
organization, variability of the surface glycoproteins, host range and pathogenicity. 
Both influenza A and B viruses contain eight segments of negative-strand RNA, 
whereas influenza C virus contains only seven segments (Cheung & Poon, 2007). 
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Influenza A virus has a wide range of hosts including domestic and wild birds, pigs, 
horses, mink, seals, bats, as well as humans, while influenza virus types B and C infect 
predominantly humans (Tong et al, 2013; Webster et al, 1992). Every year, influenza 
virus types A and B cause epidemics in human population. However, only influenza A 
viruses have been responsible for pandemic outbreaks.  
Influenza A virus is an enveloped virus of 80-120 nm in diameter with eight 
segments of negative-strand RNA encoding up to 15 proteins depending on the strain. 
The proteins include hemagglutinin (HA), neuraminidase (NA), matrix protein 1 (M1), 
proton channel protein (M2), nucleoprotein (NP), polymerase acid protein (PA), 
polymerase basic protein 1 and 2 (PB1 and PB2), non-structural protein 1 (NS1) and 
nuclear export protein (NEP, also known as NS2) (Medina & Garcia-Sastre, 2011). In 
some strains, there are additional proteins, such as PB1-F2, PB1-N40, and PA-X (Chen 
et al, 2001; Jagger et al, 2012; Wise et al, 2009). Recently, two novel proteins expressed 
from the PA segment, PA-N155 and PA-N182, have been identified (Muramoto et al, 
2013).  
Three viral proteins HA, NA and M1 are embedded in a lipid envelope which is 
derived from the plasma membrane of the infected cell (Figure 1). HA and NA are 
glycoproteins that form trimers and tetramers on the virion surface, respectively. Each 
RNA segment is associated with multiple copies of NP and with three polymerase 
subunits, PB1, PB2 and PA (Moeller et al, 2012). This large complex, called viral 
ribonucleoprotein (vRNP), is surrounded by a layer of M1 and stabilized by NEP. Other 
proteins, such as NS1, PB1-F2, PB1-N40, PA-X, PA-N155, and PA-N182, are non-
structural proteins that are synthesized during virus replication in the cell (Muramoto et 
al, 2013). 
 
Figure 1. Schematic representation of influenza A virus.  
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Depending on the differences in the surface glycoproteins, influenza A viruses are 
classified into 162 subtypes with at least 18 HA (H1 – H18) and 11 NA (N1 – N11) 
subtypes having been documented to date (Tong et al, 2013). For example, influenza 
virus subtypes H1, H2, and H3 are found in humans, subtypes H5, H7 and H9 in birds 
(Medina & Garcia-Sastre, 2011). 
1.2.2. The life cycle of influenza virus 
The influenza virus life cycle (Figure 2) can be divided into the following stages: 
(i) attachment to the cell surface; (ii) virus entry by endocytosis; (iii) release of vRNPs 
into the cytoplasm; (iv) migration of vRNPs into the nucleus; (v) transcription and 
replication of the viral RNAs; (vi) translation of viral proteins; (vii) export of the 
vRNPs from the nucleus; (viii) assembly and budding at the host cell plasma membrane 
(Nayak et al, 2009; Samji, 2009; Sun & Whittaker, 2013).  
Figure 2. Influenza virus replication cycle. 
HA binds to a sialic acid receptor on the plasma membrane of the infected cell. 
Interestingly, human influenza A strains bind to α2,6-linked sialic acid receptors, avian 
influenza strains bind to α2,3-linked sialic acids, and swine influenza strains can 
recognize both types of receptors (Skehel & Wiley, 2000; Suzuki et al, 2000). However, 
it has been recently shown that the avian influenza A (H7N9) virus binds to both 
human-like α2,6- and avian-like α2,3-linked sialic acids (van Riel et al, 2013). After 
binding, the virus particle enters the host cell by clathrin-dependent receptor-mediated 
endocytosis (Samji, 2009). The low pH (5 – 6) in the endosome induces conformational 
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changes in HA that trigger the fusion of the viral envelop and the endosomal membrane 
(Han et al, 2001). At the same time, the M2 ion channel transports protons into the virus 
particle interior. This evokes conformational changes in M1 resulting in the disruption 
of M1-vRNPs interactions (Pinto & Lamb, 2006). When fusion of the viral envelope 
and the endosomal membrane occurs, vRNPs are released into the cytoplasm and they 
migrate to the nucleus. In the nucleus, the site of influenza virus replication and 
transduction, vRNPs serve as templates for the production of mRNA and cRNA. The 
RNA polymerase formed by PB1, PB2 and PA subunits catalyzes the synthesis of 
mRNAs and cRNAs (Amorim & Digard, 2006). The mRNAs are exported from the 
nucleus to allow their translation in the cellular ribosomes. The synthesized viral 
proteins NP, M1, NS2 and polymerase subunits are then imported into the nucleus for 
vRNP assembly. The newly formed vRNPs are exported from the nucleus and directed 
to the apical plasma membrane where assembly of progeny virions occurs (Nayak et al, 
2009). At this point, NA removes sialic acid residues from glycoproteins and 
glycolipids, thus allowing the new virus particles to bud off from the host cell surface 
and to repeat the infection cycle. 
1.2.3. Evolution of influenza viruses  
It is well known that influenza genes HA and NA mutate frequently. This process, 
referred to as antigenic drift, leads to the emergence of new virus strains with different 
antigenic profiles (Figure 3A). These new strains are not recognized by the antibodies 
that were produced against previous strains, and as a result an annual influenza 
epidemic can occur (Dixit et al, 2013; Medina & Garcia-Sastre, 2011). In addition, the 
segmented organization of influenza genome allows genetic reassortment between two 
or more viruses infecting the same cell. This process is called antigenic shift and it leads 
to the emergence of new subtypes (Figure 3B). In the case of influenza A viruses with a 
broad host range, reassortment events sometimes result in the emergence of new 
influenza subtypes to which the human population is naïve. Most of the pandemic-
causing viruses over the last 100 years as well as the new avian influenza A (H7N9) 
virus identified in China in 2013, are thought to have emerged through genome 
reassortant of viruses from human, avian and/or swine hosts (Li et al, 2013; Medina & 
Garcia-Sastre, 2011; Shin & Seong, 2013). 
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Figure 3. Evolution of influenza A viruses. 
 
1.3. Prevention and treatment of influenza  
Currently, two types of influenza virus vaccines and four directly acting antiviral 
drugs are approved by FDA for the prevention and treatment of influenza virus 
infections. Vaccination is the primary method for prophylactic protection from 
influenza virus infection. Routine annual influenza vaccination is recommended for 
persons under the age of 6 months, persons over the age of 50 years, health care 
workers, pregnant women and people of all ages with chronic respiratory diseases, heart 
or renal diseases, diabetes or immunosuppression due to disease or treatment (Baguelin 
et al, 2012). Due to the high mutation rate of influenza surface glycoproteins new 
seasonal influenza vaccines need to be produced every year, a major task since the 
production of influenza vaccines takes 6 to 8 months. Moreover, the vaccine should be 
administered about 4 weeks before the start of the next epidemic season (in the 
Northern Hemisphere the influenza season starts in December, in the Southern 
Hemisphere in May). WHO Global Influenza Surveillance and Response System issues 
a recommendation about the composition of influenza virus vaccines. Usually seasonal 
influenza vaccines contain two influenza A (H1N1 and H3N2) subtypes, and one 
influenza B (trivalent vaccine) or two influenza B strain (quadrivalent vaccine) (Centers 
for Disease & Prevention, 2013). There are two types of licensed influenza vaccines. 
Inactivated virus containing vaccines are available in an injectable form, whereas live 
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attenuated virus containing vaccines are administered as an intranasal spray (FluMist) 
(Lee et al, 2014; Luksic et al, 2013). In practice, the seasonal influenza vaccines will be 
effective in prevention and control of seasonal epidemics if they are produced and 
delivered in time. However, the effectiveness can differ from season to season and it 
will depend on the circulating influenza strains (Centers for Disease & Prevention, 
2013; Gefenaite et al, 2014; Valenciano et al, 2011). Moreover, seasonal influenza 
vaccines are completely ineffective in the prevention of the occasional influenza 
pandemics caused by new emerging strains.  
Currently, four licensed anti-influenza drugs are available to cure disease and 
shorten the infection period. These antivirals target two major surface glycoproteins M2 
(amantadine and rimantadine) and NA (oseltamivir and zanamivir) (Table 1). 
Amantadine and rimantadine target the M2 ion channel blocking transport of protons 
into the virion interior and are effective against influenza virus type A, but not B and C 
(McKimm-Breschkin, 2013b). Both antivirals are approved for adults, amantadine in 
addition for children older than one year old. In 1999, FDA approved two NA 
inhibitors, oseltamivir (GS4104, Tamiflu®) and zanamivir (GG167, Relenza®), for 
treatment and prevention of acute infections caused by influenza virus types A and B. 
These agents act by blocking the functions of NA, release and spreading of progeny 
virions at the late stage of virus replication is prevented. Oseltamivir is approved for 
adults, whereas zanamivir is approved for adults and for children over 7 years of age.  
Resistance to the licensed virus-targeted antivirals has developed rapidly. 
Amantadine resistance caused by a S31N mutation in the M2 protein has been described 
in all human (H1N1, H3N2, and H1N1pdm09) and avian (H5N1 and H7N9) influenza 
A strains circulating globally (Bright et al, 2005; Hayden & de Jong, 2011; Nelson et al, 
2009; Zhou et al, 2013). The S31N mutation does not decrease viral replication or 
transmissibility (Hayden & de Jong, 2011). In addition, other amantadine resistance-
conferring mutations such as A30T, L26F, and V27A have been detected (Deyde et al, 
2007). Oseltamivir resistance caused by the H275Y mutation in NA has been identified 
among the clinical isolates of human (H1N1, H3N2, and H1N1pdm09) and avian 
(H5N1) influenza A viruses (Dharan et al, 2009; Hayden & de Jong, 2011; Le et al, 
2005; Meijer et al, 2009). It has been demonstrated that the H275Y mutation leads to 
reduction of viral infectivity and virulence in seasonal influenza H1N1 viruses (Hayden 
& de Jong, 2011). In addition, other oseltamivir-resistance mutations in NA, such as 
E119V, N294S, R292K, D198N/E, I222T/V/M, and R292K have been described 
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(McKimm-Breschkin, 2013b; Moscona, 2009). During the 2009 pandemic, patients 
infected by viruses with the H275Y mutation were successfully treated with zanamivir 
(Uyeki, 2009).  
Thus, the applicability of M2- and NA-directed licensed antiviral drugs is limited 
because the globally circulating influenza virus strains have acquired resistance to 
amantadine and/or oseltamivir (Hayden & de Jong, 2011; McKimm-Breschkin, 2013a). 
Nowadays, there are ongoing investigations of new potential agents targeting both virus 
proteins and cellular host factors. Many of these are in advanced stages of clinical 
development and are intended to be used in the treatment of influenza virus infection in 
combination therapy with licensed M2 and NA inhibitors (Haasbach et al, 2013a; Tarbet 
et al, 2012). 
Table 1. FDA approved anti-influenza drugs. 
Name Target Chemical structure EC50 
Amantadine M2 
 
A: 0.15 – 1.6 µMa 
Rimantadine M2 
 
A: 14 nM
b
  
Oseltamivir  
(GS4104, Tamiflu®) 
NA 
 
A: 1.34 nM
c
 
B: 10.3 nM
c
 
Zanamivir  
(GG167, Relenza®) 
NA 
 
A: 1.64 nM
c
 
B: 6.49 nM
c
  
Note: EC50 represents effective concentration required to inhibit infectious viral yield by 50%;  
a (Shin & Seong, 2013); b (Savinova et al, 2009); c (Yamashita et al, 2009).         
   
1.3.1. Novel virus-directed antiviral agents 
1.3.1.1. M2 ion channel blockers 
Two novel compounds, I5 and I9 (Table 2), have been discovered by virtual 
screening by docking and pharmacophore modeling against influenza A (H3N2 and 
H1N1pdm09) viruses (Tran et al, 2011). However, detailed studies of their efficacy in 
vitro and in vivo are lacking. 
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Table 2. M2 ion channel blockers. 
Name Chemical structure EC50 Clinical development 
I5 
 
n.a. Only virtual screen 
I9 
 
n.a. Only virtual screen 
n.a., not available. 
 
1.3.1.2. Neuraminidase inhibitors 
In addition to oseltamivir and zanamivir, there are other NA inhibitors, peramivir 
(BCX-1812, RWJ-270201) and laninamivir (CS-8958, Inavir®) (Table 3) that have 
been used in the prophylaxis and treatment of influenza virus infection in several 
countries (Sidwell & Smee, 2002; Yamashita et al, 2009). Peramivir and laninamivir are 
already approved in Japan, and peramivir also in South Korea (Hayden, 2013). 
However, it has been reported that oseltamivir-resistant strains with the H275Y 
mutation were insensitive to peramivir treatment (McKimm-Breschkin, 2013b). At the 
same time, several pyrrolidine derivatives such as A-192558 and A-315675 (Table 3) 
have been shown to possess antiviral activity against influenza virus types A and B 
(Kati et al, 2002; Wang et al, 2001). Importantly, there is a report that A-315675 retains 
activity against oseltamivir- and zanamivir-resistant influenza types A and B (De 
Clercq, 2006).  
1.3.1.3. Hemagglutinin inhibitors 
HA is a critical viral protein that can potentially be targeted to treat influenza 
infections caused by M2 and/or NA inhibitor-resistant strains. Taking into account the 
fact that there are 18 HA subtypes, selection and rational drug design of broad-spectrum 
influenza virus inhibitors targeting HA is a challenging task. A number of 
investigational protein-based peptides have been described (Table 4). For instance, 
Jones and colleagues identified a 20-amino-acid peptide (EB, as an entry blocker) with 
a broad-spectrum antiviral activity against influenza A (H5N1) and B viruses in vivo 
and in vitro (Jones et al, 2006). This peptide specifically binds to HA and inhibits its 
attachment to the cellular receptor. 
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Table 3. NA inhibitors and their antiviral activity against influenza virus infection. 
Name Chemical structure EC50  Clinical development 
Peramivir 
(BCX-1812, 
RWJ-270201) 
 
A: 0.2 nM
a
  
B: 8.5 nM
a
 
Licensed in Japan and South 
Korea; phase III for treatment 
of influenza A and B 
Laninamivir 
(CS-8958, 
Inavir®) 
 
A: 2.5 nM
b
  
B: 18.9 nM
b
 
Licensed in Japan; phase III 
for treatment of influenza A 
and B 
A-192558 
 
A: 0.2 nM
c
  
B: 8 nM
c
 
Not in clinical development 
A-315675 
 
A: 0.4 nM
b
  
B: 5.9 nM
b
 
Not in clinical development 
a (Kati et al, 2002); b  (Yamashita et al, 2009); c (Wang et al, 2001). 
 
Another study has described a number of N-stearoyl peptides that mimic sialic acid and 
inhibit virus attachment to the cell (Matsubara et al, 2010). Peptides C18-s2(1-8) and 
C18-s2 (1-5) have exhibited broad-spectrum antiviral activity against influenza A 
(H1N1 and H3N2) strains in vitro. Based on a docking simulation, the authors 
demonstrated that the peptides were recognized by a receptor-binding site in HA 
(Matsubara et al, 2010). A 16-amino-acid peptide (Flufirvitide) derived from a fusion 
initiation region of HA has been demonstrated to block influenza A virus infection 
(Badani et al., 2011). Currently, flufirvitide is in phase I clinical trials. Recently, 12-20 
amino acid peptides containing highly conserved sequences of HA1 and HA2 subunits 
have been designed in silico and nine peptides have been tested against influenza A 
(H1N1 and H5H1) strains in vitro (Jesus et al, 2012). Based on the docking results, the 
authors proposed that the peptides bind to the HA stalk and prevent the HA 
conformational changes required for membrane fusion events (Lopez-Martinez et al, 
2013). 
Moreover, a number of small-molecule inhibitors that suppress influenza virus 
infection by preventing low pH-mediated conformation changes of HA and HA 
maturation have been described (Table 5). For instance, Bodian and colleagues identified 
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benzoquinone and hydroquinone compounds that bind to HA and stabilize its non-
fusogenic conformation (Bodian et al, 1993).  
Table 4. Peptides blocking HA and their antiviral activity against influenza virus infection. 
Name Chemical structure EC50  Clinical development 
EB NH2-
RRKKAAVALLPAVLLALLAP-
COOH 
4.5 μMa Not in clinical 
development  
C18-s2(1-8) C17H35CO-ARLPRTMV-NH2 3 – 4.2 μM
b
  Not in clinical 
development 
C18-s2(1-5) C17H35CO-ARLPR-NH2 1.6 – 1.9 μM
b
 Not in clinical 
development 
Flufirvitide n.a. n.a. Phase I 
a (Jones et al, 2006); b (Matsubara et al, 2010); n.a., not available. 
 
Recent research has revealed that a widely used food preservative tert-butyl 
hydroquinone (TBHQ) is a very promising lead compound for the development of 
antivirals targeting HA (Antanasijevic et al, 2013). It was demonstrated that TBHQ 
inhibits HA-mediated entry of influenza A (H7N7 and H3N2) viruses. Based on the 
limited proteolysis assay data, the authors claimed that TBHQ could bind to a specific 
stem-loop element and block the pH-induced conformation of HA necessary for the 
fusion of viral and endosomal membranes (Antanasijevic et al, 2013). Other 
compounds, BMY-27709, CL-61917 (N-substituted piperidine), and CL-62554, 
blocking the conformational changes of HA specifically inhibited replication of 
influenza A (H1N1 and H2N2) subtypes but not the H3N2 (Luo et al, 1996; Plotch et al, 
1999). Analysis of mutant viruses resistant to these compounds revealed mutations 
clustered in the stem region of the HA homotrimer near to the HA2 fusion peptide part. 
Similarly, the antiviral drug arbidol (Umifenovir) which is widely used in Russia and 
China, inhibits the early membrane fusion events in influenza A and B virus infections 
and mutations associated with resistance to this compound have been mapped to HA2 
(Boriskin et al, 2008; Leneva et al, 2009). Recently, two novel compounds, MBX2329 
and MBX2546, binding in the stem region of the HA trimer and inhibiting HA mediated 
fusion have been identified (Basu et al, 2014).  
Interestingly, salicylanilides have a wide range of biological activities including 
antiviral properties (Kratky & Vinsova, 2011). The nitrothiazole derivative of 
salicylamide, nitazoxanide (Alinia®) (Table 5) is an FDA-approved orally administered 
antiprotozoal drug used in the treatment of diarrhea in children and adults caused by 
Cryptosporidium or Giardia. This compound and its active circulating metabolite 
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tizoxanide are also known to be effective against influenza A (H1N1 and H5N9) viruses 
in vitro (Rossignol et al, 2009). The authors clearly demonstrated that during virus 
infection, nitazoxanide acts at the post-translational level by blocking the HA 
maturation therefore impairing intracellular trafficking of HA and preventing insertion 
into the cellular membrane. Currently, nitazoxanide is undergoing phase III clinical 
trials for the treatment of acute uncomplicated influenza virus infections as well as in 
phase II/III clinical trials for the treatment of chronic hepatitis C virus (HCV) infection. 
Table 5. HA inhibitors and their antiviral activity against influenza virus infection. 
Name Chemical structure EC50 Clinical development 
TBHQ 
 
6 µMa Not in clinical development 
BMY-27709 
 
3 – 8 µMb Not in clinical development 
CL-61917 
 
6 µMc Not in clinical development 
CL-62554 
 
25 µMc Not in clinical development 
Arbidol 
(Umifenovir) 
 
5.6 – 23 µMd Approved in Russia and 
China; phase IV for treatment 
of influenza and common cold 
Nitazoxanide 
(Alinia®) 
 
1.5 – 3 µMe Approved as antiprotozoal 
agent; phase III for influenza 
treatment 
Tizoxanide 
 
 
1.5 – 3 µMe Not in clinical development 
MBX2329 
 
0.3 – 5.9 µMf Not in clinical development 
MBX2546 
 
0.5 – 5.8 µMf Not in clinical development 
a (Antanasijevic et al, 2013); b (Luo et al, 1996); c (Plotch et al, 1999); d (Boriskin et al, 2008);  
e (Rossignol et al, 2009); f (Basu et al, 2014). 
 
Finally, a number of natural compounds interact with the HA protein and possess 
a broad spectrum anti-influenza activity (Table 6). For example, curcumin, a natural 
ingredient in curry, a commonly used coloring agent and spice in food, has been found 
to block influenza A (H1N1 and H6N1) virus entry targeting HA in vitro (Chen et al, 
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2013). Moreover, curcumin was shown to be active against coxsackievirus B3, herpes 
simplex virus (HSV), hepatitis B virus (HBV), and human immunodeficiency virus 
(HIV) (Kutluay et al, 2008; Rechtman et al, 2010; Si et al, 2007; Sui et al, 1993). 
Recently, a number of curcumin analogues with anti-influenza activities, 
tetrahydrocurcumin and petasiphenol, have been described (Ou et al, 2013).  
Table 6. Natural compounds blocking of HA and their antiviral activity against influenza virus 
infection. 
Name Chemical structure EC50 Clinical development 
Curcumin 
 
0.17 µMa Phase II/III against 
cancer 
Tetrahydro-
curcumin  
 
15 μMa Not in clinical 
development 
Petasiphenol 
 
14.65 μMa Not in clinical 
development 
EGCG 
 
22 – 28 µMb Phase II/III as antiviral 
ECG 
 
22 – 40 µMb Phase II/III against 
Alzheimer’s disease 
AL-1 
 
7 – 15 µMc Not in clinical 
development 
a (Ou et al, 2013); b (Song et al, 2005); c (Chen et al, 2009). 
 
Moreover, it has been shown that catechins, bioactive ingredients in green tea, are able 
to inhibit HA. For example, epigallocatechin gallate (EGCG) and epicatechin gallate 
(ECG) displayed significant activity against influenza A (H1N1 and H3N2) and B 
viruses in vitro (Song et al, 2005). Recently Kim and colleagues found that the 
conformational changes in HA result from EGCG-mediated viral lipid membrane 
damage rather than from any direct interaction between EGCG and viral HA (Kim et al, 
2013). In addition, andrographolides from a herb Andrographis paniculata which is 
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widely used in Asian countries, such as 14-α–lipoyl andrographolide (AL-1), were 
shown to be active against avian influenza A (H9N2 and H5N1) and human influenza A 
(H1N1) viruses in vitro (Chen et al, 2009). 
1.3.1.4. Polymerase inhibitors 
The viral RNA polymerase consisting of PB1, PB2 and PA subunits is a key 
enzyme responsible for the synthesis of viral mRNA and cRNA. A number of 
compounds blocking the functions of viral polymerase have been identified (Table 7), 
some of which are already in clinical use. Ribavirin (Virazole®) is a guanosine analog 
which inhibits a broad range of RNA and DNA viruses (Jonsson et al, 2008; Khan et al, 
2008; Markland et al, 2000). The synthesis and antiviral activity of ribavirin were 
reported more than 40 years ago. Three mechanisms of action have been proposed for 
this compound: (i) ribavirin may target inosine 5’-monophosphate dehydrogenase, a key 
cellular enzyme involved in the biosynthesis of GTP, or (ii) ribavirin triphosphate may 
inhibit the function of a viral RNA polymerase or (iii) ribavirin may inhibit a guanine 
pyrophosphate “cap” on the 5’-end of viral mRNA (De Clercq, 2006; Ilyushina et al, 
2008; Markland et al, 2000). An aerosol form of ribavirin has been approved for the 
treatment of respiratory syncytial virus infection, and in combination with pegylated 
interferon (IFN)-α for the treatment of chronic HCV infection (De Clercq, 2004). 
Viramidine (Taribavirin) is a 3-carboxamidine prodrug of ribavirin that has lower 
toxicity and a shorter life time in vivo (Wu et al, 2006). Ribavirin and viramidine were 
shown to exert antiviral effects against a range of influenza A (H1N1, H3N2, and 
H5N1) and B viruses in vitro and in vivo (Sidwell et al, 2005). Currently, viramidine is 
undergoing evaluation in phase II/III clinical trials for treatment of influenza virus 
infection and in phase III for HCV treatment (Hayden, 2013).  
Favipiravir (T-705) has been shown to exert antiviral effect against influenza 
virus and some other RNA viruses including arenaviruses, bunyaviruses, West Nile 
virus, yellow fever virus, and foot-and-mouth disease virus (Baranovich et al, 2013; 
Furuta et al, 2009). There are experimental findings indicating that the favipiravir 
metabolite inhibits RNA polymerase of influenza virus without affecting the synthesis 
of host cellular DNA and RNA, in the way of ribavirin (Furuta et al, 2005). The authors 
suggested that the high-error rate viral RNA polymerase false-recognizes nucleotides 
more frequently compared to the cellular RNA polymerase (Furuta et al, 2009). To date, 
no favipiravir-resistant virus variants have been reported (Hayden, 2013). Favipiravir is 
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currently undergoing clinical evaluation in Japan for treatment of influenza infections 
with virus types A and B. 
A number of other molecules targeting the activity of influenza virus RNA 
polymerase, have been identified by high-throughput screening and of these, 
compounds 367 and ASN2 are thought to act through the PB1 subunit since mutations 
in this protein (H456P and Y499H, respectively) have been associated with elevated 
resistance to these drugs (Ortigoza et al, 2012; Su et al, 2010). 
Table 7. Polymerase inhibitors and their antiviral activity against influenza virus infection. 
Name Chemical structure EC50 Clinical development 
Ribavirin 
(Virazole®) 
 
2 – 22 µMa Phase II/III for treatment of 
influenza; approved for 
treatment of respiratory 
syncytial virus and HCV 
Viramidine 
(Taribavirin) 
 
8 – 131 µMa Phase II/III for treatment of 
influenza  
Favipiravir  
(T-705) 
 
11.4 – 17 µMb Phase III for treatment of 
influenza  
Compound 367 
 
n.a. Not in clinical development 
ASN2 
  
3 µMc Not in clinical development 
a (Sidwell et al, 2005); b (Baranovich et al, 2013); c (Ortigoza et al, 2012); n.a., not available.  
 
1.3.1.5. Non-structural protein 1 inhibitors  
The multifunctional NS1 protein is a virulence factor of influenza virus. It has 
been shown that NS1 can inhibit the production of antiviral mRNAs particularly IFN-β 
mRNA by interacting with the cleavage and polyadenylation specificity factor 
(CPSF30) required for the 3’-end processing of cellular pre-mRNAs (Das et al, 2008). 
NS1 interacts with the second and third zinc finger domains of CPSF30 (F2F3) and in 
vitro the expression of the F2F3 fragment has been shown to inhibit viral replication by 
blocking the CPSF30-binding site of NS1 (Twu et al, 2006). Indeed, virus yield in 
F2F3-expressing cells was reduced by 35- to 60-fold in comparison to control cells. The 
X-ray crystal structure of the C-terminal domain of the influenza A virus NS1 protein in 
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complex with the CPSF30 F2F3 fragment solved at the 1.95-Å resolution suggested 
possible antiviral approaches aimed at disrupting this interaction (Das et al, 2008). 
However, as far as is known no compounds targeting the CPSF30-binding pocket of 
NS1 have been developed. 
1.3.1.6. Nucleoprotein inhibitors 
NP is the most abundant viral protein expressed during influenza virus infection. 
NP is a multifunctional protein, which accumulates in the nucleus at an early stage of 
infection and migrates to the cytoplasm during virus assembly and maturation (Kao et 
al, 2010). There are recent findings that NP may be a druggable target for influenza 
treatment and prophylaxis. For instance, Kao and colleagues identified nucleozin (FA-4; 
Table 8) as a potent inhibitor of NP (Kao et al, 2010). Nucleozin triggers the 
aggregation of NP and inhibits its nuclear accumulation. Nucleozin has inhibited 
infection of influenza A (H1N1, H3N2, and H5N1) in vitro and protected mice infected 
with avian influenza A (H5N1) virus (Kao et al, 2010). The Y289H mutation in NP was 
shown to be crucial in the development of nucleozin resistance. In addition, a nucleozin 
analog, compound 3061 (FA-2), has inhibited replication of influenza A (H1N1) virus 
in both cell culture and a mouse model, with resistance to this drug appearing as a result 
of Y52H mutation in NP (Su et al, 2010). 
Table 8. NP inhibitors and their antiviral activity against influenza virus infection. 
Name Chemical structure EC50 Clinical development 
Nucleozin (FA-4) 
 
70 – 333 nMa Not in clinical 
development 
3061 (FA-2) 
 
n.a. Not in clinical 
development 
a (Kao et al, 2010); n.a., not available. 
 
1.3.1.7. Nucleic acid-based antiviral drugs 
Nucleic acid-based antiviral drugs including antisense oligonucleotides and small 
interfering RNA (siRNA) were found to exert potent antiviral effects against influenza 
and other viruses (DeVincenzo, 2012; Zhang et al, 2011; Zhou et al, 2007). They 
specifically target viral genes but have no impact on host gene expression, avoiding 
potential side effects (Zhang et al, 2011). Antisense oligonucleotides targeting PA, PB1, 
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PB2, NP and NS1 genes were shown to be able to inhibit the replication of influenza A 
virus (H1N1 and H5N1) in vitro and in vivo (Wu et al, 2008; Zhang et al, 2011). 
Similarly, M2-specific and NP-specific siRNAs have been tested to be effective against 
influenza A virus (H5N1, H1N1, and H9N2) in vitro and in vivo (Zhou et al, 2007). In 
addition, a phosphorodiamidate morpholino oligomer AVI-7100 targeting expression of 
the M1 and M2 genes has been designed (Iversen et al., 2012). AVI-7100 is effective 
against influenza A (H1N1 and H3N2) in both mice and ferrets. Currently, AVI-7100 is 
in phase I clinical trials as a candidate agent for treatment of influenza infections.  
1.3.2. Host-directed antiviral agents 
The progress in our understanding of virus-host interactions made over the last 
decade has inspired alternative strategies of controlling and treating viral infection. Of 
these, targeting host factors essential for virus biology is an especially attractive 
approach since it is associated with two potential advantages. First, resistance against 
host-directed antivirals is expected to emerge substantially more slowly than against 
drugs targeting highly evolvable viral proteins. Second, compounds interacting with 
host factors might possess a broad-spectrum antiviral potential and, as a result, higher 
clinical value. Genome-wide siRNA screens have identified multiple host genes and 
molecular networks crucial for influenza virus (Karlas et al, 2010; Konig et al, 2010) 
and several other RNA virus replication processes (Li et al, 2009; Sessions et al, 2009; 
Zhou et al, 2008). In addition, a number of quantitative proteomic techniques have been 
applied for evaluating virus-host cell interactions (Dove et al, 2012; Lietzen et al, 2011; 
Munday et al, 2012). In view of the fact that genome-wide screens could contain false 
positives, Watanabe and colleagues analyzed 1449 candidate genes identified in six 
recently published independent genome-wide screens. They found 128 human genes 
affected by influenza virus that were present in at least two of the screens (Watanabe et 
al, 2010). In the past decade the roles of signaling pathways, including Ras-dependent 
Raf/MEK/ERK, PI3K/Akt (phosphatidylinositol 3-kinase), NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) signaling and protein kinase C (PCK) 
cascades, in efficient influenza virus replication have also been well established 
(Ludwig et al, 2003; Planz, 2013). Importantly, signaling pathways have proved to be 
ideal targets in cancer therapy, and a large number of specific and highly effective 
inhibitors have been generated aimed at those targets (Engelman, 2009; Fresno Vara et 
al, 2004; Wong et al, 2010).  
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This chapter summarizes our knowledge about anti-influenza virus activity of 
molecules targeting host proteins and host components of signaling pathways. Some of 
these molecules, for example DAS181 and aprotinin, are undergoing clinical trials, 
some are approved for treatment of influenza virus infections in some countries. The 
other types of host-directed antivirals have been originally developed as anticancer 
therapeutics and a subset of these molecules are either approved by FDA or in the 
clinical development stage. Given that de novo drug development is a notoriously 
lengthy and costly endeavor, repurposing cancer drugs for antiviral use opens up an 
exciting new avenue of clinical research and, as will be discussed in detail, it provides 
an innovative experimental approach to understanding influenza virus biology. 
1.3.2.1. Agents cleaving sialic acid  
Influenza viruses require sialic acid-containing cell receptors for entry, therefore 
inhibitors of virus interaction with sialic acid have potential uses in therapeutic 
intervention. One promising candidate for influenza treatment is DAS181 (Fludase®), 
which is currently in phase II clinical trials (Moss et al, 2012). DAS181 is a 
recombinant fusion protein (46 kDa) composed of a catalytic domain from Actinomyces 
vircosus sialidase linked with a cell surface-anchoring domain of human amphiregulin 
(Malakhov et al, 2006). DAS181 becomes attached to a respiratory epithelium cell and 
cleaves off the sialic acid from the cell surface, thus preventing viral adsorption. 
DAS181 removes both human-like α2,6- and avian-like α2,3-linked sialic acids from 
host cells and it has been shown to be active against human (H3N2 and H1N1pdm09), 
including oseltamivir-resistant strains and avian (H5N1) influenza A viruses in vitro 
with EC50 values in a range of 0.04 – 0.9 nM and it is also effective in vivo (mice, 
ferrets) (Belser et al, 2007; Moss et al, 2012; Triana-Baltzer et al, 2009). These findings 
support the belief that DAS181 may be able to exert antiviral activity against a broad 
range of influenza viruses. Moreover, an inhaled administration of DAS181 was shown 
to protect against parainfluenza virus (Chen et al, 2011). Virus resistance to DAS181 
was reported to be minimal and unstable (Triana-Baltzer et al, 2009). 
1.3.2.2. Protease inhibitors 
Cleavage of HA0 to HA1 and HA2 by cellular proteases is a crucial step in 
influenza virus infection since it is necessary for the fusion of the viral envelop and the 
endosomal membrane. Therefore HA-cleaving cellular trypsin-like proteases represent 
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potential targets for antiviral drug development. It was already demonstrated that a 
number of protease inhibitors widely used for the treatment of pancreatitis, including 
leupeptin, camostat, nafamostat (Futhan), gabexate and aprotinin (Trasylol®) (Table 9), 
are active against influenza virus types A and B in vitro and in vivo (Hosoya et al, 1992; 
Lee et al, 1996; Noma et al, 1998; Tashiro et al, 1987; Zhirnov et al, 2011). 
Interestingly, none of the protease inhibitors possessed activity against measles virus 
(MeV), respiratory syncytial virus or parainfluenza virus type 3 (Hosoya et al, 1992).  
Table 9. Protease inhibitors and their antiviral activity against influenza virus infection. 
Name Chemical structure EC50 Clinical development 
Leupeptin 
 
n.a. Not in clinical development 
Camostat 
(Fiopan) 
 
A: 4 μMa 
B: 11 μMa 
 
Not in clinical development 
Nafamostat 
(Futhan) 
 
A: 1.2 μMa  
B: 4.3 μMa 
 
Approved as anticoagulant  
Gabexate 
(FOY) 
 
A: 738 μMa  
B: 417 μMa 
Phase IV for anticoagulation 
treatment 
Aprotinin 
(Trasylol®) 
58-amino acid polypeptide A: 26 μMa  
B: 39 μMa 
Approved in Russia for 
treatment of influenza; phase 
III in vascular surgery 
a (Hosoya et al, 1992); n.a., not available. 
 
Leupeptin is a small peptide produced by actinomycetes capable of inhibiting serine, 
cysteine and threonine proteases. Tashiro and colleagues showed that leupeptin 
suppresses virus replication in mice co-infected with influenza virus and 
Staphylococcus aureus (Tashiro et al, 1987). Nafamostat and gabexate are synthetic 
serine protease inhibitors used as anticoagulant drugs (Maruyama et al, 2011; Yuksel et 
al, 2003). Aprotinin is a 58-amino acid polypeptide purified from bovine lungs. It has 
been shown that aprotinin can suppress proinflammatory cytokines, such as interleukin 
(IL)-6, IL-1b and tumor necrosis factor (TNF)-α, in vitro and in vivo (Pan et al, 2011). 
Aerosol administration of aprotinin is now approved as an anti-influenza treatment in 
Russia (Zhirnov et al, 2011). 
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1.3.2.3. Vacuolar proton-ATPase inhibitors 
The v-ATPase is a multisubunit complex with a molecular mass exceeding 850 
kDa and responsible for the acidification of endosomes. v-ATPase consists of a 
cytosolic V1-domain, containing eight subunits (A, B, C, D, E, F, G, and H), and a 
trans-membrane proton translocation V0-domain, containing five subunits (a, d, c, c′, 
and c″) (Kane & Smardon, 2003). Human v-ATPase plays important roles in normal 
physiological processes of the cell as well as in some severe diseases and cancers. 
Therefore, v-ATPase has proved to be a potential therapeutic target in cancer therapy 
(Dreisigacker et al, 2012; Lebreton et al, 2008; Wiedmann et al, 2012). Several studies 
have identified a role of v-ATPase in influenza virus infection (Drose & Altendorf, 
1997; Guinea & Carrasco, 1995; Marjuki et al, 2011; Müller et al, 2011). Genome-wide 
siRNA screening revealed a number of v-ATPase genes necessary for influenza virus 
entry, including ATP6V1A, ATP6V1B2, ATP6V0B, ATP6V0C, ATP60D1 and ATP6AP1 
(Karlas et al, 2010; Konig et al, 2010), and for other RNA viruses such as West Nile 
virus, Dengue virus (DENV), and HIV (Konig et al, 2008; Krishnan et al, 2008; 
Sessions et al, 2009).  
There are several groups of v-ATPase inhibitors differing in their structural 
characteristics and mechanism of action (Table 10). A group of plecomacrolide 
antibiotics such as bafilomycin A1 and concanamycin A block the functions of v-
ATPases and P-ATPases but not mitochondrial F-ATPase (Drose & Altendorf, 1997; 
Guinea & Carrasco, 1995). A second group of v-ATPase inhibitors is archazolides, 
which specifically inhibit the functions of v-ATPases (Huss et al, 2005). It has been 
shown that archazolid A and B can hinder the migration of invasive cancer cells in vitro 
and in vivo (Wiedmann et al, 2012). Benzolactone enamides represent a third group of 
v-ATPase inhibitors, these compounds include salicylihalamides A and B that 
specifically block mammalian v-ATPase (Boyd et al, 2001). It has been reported that 
salicylihalamide A binds irreversibly to the trans-membrane V0-domain of v-ATPase 
(Xie et al, 2004). Lebreton and colleagues synthesized saliphenylhalamide (SaliPhe), a 
more stable phenyl derivative of salicylihalamide A (Lebreton et al, 2008). Moreover, 
SaliPhe selectively inhibited the growth of tumorigenic human mammary epithelial 
cells (Herbert et al, 2005). Müller and colleagues investigated antiviral activity of all 
three classes of v-ATPase inhibitors against influenza A (H1N1, H1N1pdm09, and 
H5N1) strains in vitro and compared antiviral activities of SaliPhe and bafilomycin A1 
in mice. Unlike bafilomycin A1, SaliPhe provided partial protection for mice against a 
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lethal challenge with the mouse-adapted influenza strain (Müller et al, 2011). 
Additionally, v-ATPase inhibitors, bafilomycin A1 and concanamycin A, display broad-
spectrum antiviral activity against influenza viruses, vesicular stomatitis virus and 
Semliki Forest virus (SFV) (Drose & Altendorf, 1997; Guinea & Carrasco, 1995; Perez 
& Carrasco, 1994). 
Table 10. v-ATPase inhibitors and their antiviral activity against influenza virus infection. 
Name Chemical structure EC50 Clinical 
development 
Concanamycin A 
 
0.26 – 3.1 nMa Not in clinical 
development 
Bafilomycin A1 
 
0.36 – 1.3 nMa Not in clinical 
development 
Archazolid B 
 
0.43 – 1.9 nMa Not in clinical 
development 
SaliPhe 
 
28 – 206 nMa Not in clinical 
development 
a (Müller et al, 2011). 
 
1.3.2.4. Inhibitors of signaling pathways 
Many cellular signaling pathways such as PI3K/Akt/mTOR, PCK, NF-κB and 
Raf/MEK/ERK have been demonstrated to play important roles during influenza virus 
replication (Figure 4) (Ludwig et al, 2003; Planz, 2013). Several studies have proposed 
a role of PI3K and its downstream effector Akt, also known as protein kinase B, in 
influenza virus infection (Ehrhardt & Ludwig, 2009; Ehrhardt et al, 2006; Zhirnov & 
Klenk, 2007). It was reported that anti-apoptotic PI3K/Akt signaling is activated by 
NS1 in the early/middle phases of influenza infection, therefore being able to suppress 
premature apoptosis during the later stages of infection (Ehrhardt & Ludwig, 2009; 
Zhirnov & Klenk, 2007). Moreover, Marjuki and colleagues showed that inhibition of 
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influenza virus-induced early activation of extracellular signal-regulated kinase (ERK) 
and PI3K reduce v-ATPase activity and the acidification of endosomes in infected cells 
(Marjuki et al, 2011). In addition, several studies have demonstrated a role of PKC in 
influenza virus entry (Arora & Gasse, 1998; Root et al, 2000; Sieczkarski et al, 2003). 
For example, PKCβII was shown to regulate the endocytic trafficking needed for 
influenza virus entry and infection (Sieczkarski et al, 2003).  
Figure 4. Signaling pathways activated during influenza virus infection. 
Moreover, influenza virus has been shown to induce the NF-κB pathway to support its 
own replication processes via TNF-related apoptosis-induction ligand (TRAIL) and 
FasL-induced caspase activation promoting vRNP export (Mazur et al, 2007; Wurzer et 
al, 2004). In cells, NF-κB is present in a latent, inactive dimer form through association 
with inhibitor-of-kappa-B protein (IκK) in the cytoplasm. Many different stimuli, 
including TNF-α, IL-1 or some pathogens, like viruses, activate the IκB kinase (IKK) 
complex, which mediates phosphorylation-induced degradation of IκB in the 26S 
proteasome (Scheidereit, 2006). This leads to the release of the NF-κB dimer, which is 
transferred to the nucleus where it activates expression of its specific target genes such 
as IFN-β, TRAIL and Fas (Wurzer et al, 2004). Additionally, influenza virus activates 
the Raf/MEK/ERK signaling pathway for efficient export of vRNPs from the nucleus to 
the cytoplasm (Ludwig et al, 2004; Planz, 2013; Pleschka et al, 2001). It is notable that 
cells with activated Raf/MEK/ERK signaling pathway have been found to yield high 
influenza virus titers (Ludwig et al, 2004). 
Two pan-PI3K inhibitors, LY294002 and wortmannin (Table 11), have been used 
in attempts to clarify the role of the PI3K/Akt pathway in influenza virus infection 
22 
 
(Ehrhardt et al, 2006; Zhirnov & Klenk, 2007). Treatment with LY294002 or 
wortmannin inhibited virus production and reduced virus titer in vitro (Ehrhardt et al, 
2006). Moreover, LY294002 was shown to inhibit phosphorylation of Akt and to 
accelerate apoptosis in influenza virus-infected cells (Zhirnov & Klenk, 2007). 
LY294002 is a morpholino derivative of quercetin, which inhibits PI3Kα/β/γ/δ with an 
IC50 of 0.73 μM/0.31 μM/6.6 μM/1.06 μM, respectively (Chaussade et al, 2007). 
LY294002 inhibits cell proliferation and induces apoptosis in human colon cancer cells 
in vitro and in vivo (Semba et al, 2002). Wortmannin is a steroid metabolite isolated 
from Penicillium wortmanni, which inhibits PI3K and many other PI3K-related 
molecules (Ferby et al, 1996). Neither LY294002 nor wortmannin have progressed to 
clinical development due to their unfavourable pharmacological properties (Markman et 
al, 2010). However, a wortmannin derivative, PX-866, has better pharmacological 
properties and is currently being evaluated in phase II clinical trials for the treatment of 
solid tumors. Moreover, second-generation PI3K inhibitors, NVP-BKM120, XL765 
(SAR245409), NVP-BEZ235, and NVP-BGT226, are available for oral administration 
and have better pharmacological properties than LY294002 and wortmannin. Currently, 
those compounds are in phase I/II clinical trials for the treatment of advanced solid 
tumors (Courtney et al, 2010; Markman et al, 2010; Mukherjee et al, 2012). Clearly, an 
evaluation of their antiviral potential against influenza virus infection is needed.  
A genome-wide siRNA screen identified mammalian target of rapamycin 
complex1 (mTORC1) as being involved in influenza virus replication (Konig et al, 
2010). Mata and colleagues examined naphthalimides (Table 11) that inhibited 
replication of influenza virus and vesicular stomatitis virus. Naphthalimides functioned 
by increasing expression of REDD1, a major negative regulator of the mTORC1 (Mata 
et al, 2011). Recently, Keating and colleagues demonstrated that treatment with 
sirolimus (also known as rapamycin) during primary infection of influenza A (H3N2) 
virus could achive cross-strain protection of mice against secondary infection by 
influenza A (H5N1, H7N9, and H1N1) viruses (Keating et al, 2013). The authors also 
showed that mTORC1 was required for antibody class switching and that inhibition of 
this pathway during vaccination promoted an antibody repertoire (Keating et al, 2013).  
Hoffmann and colleagues used a cell-based high-throughput screening approach 
to identify distinct groups of inhibitors and enhancers of PKCs. These authors 
demonstrated that treatment by the commercially available PKC inhibitor rottlerin 
(Table 11) reduced replication of influenza virus in vitro. In contrast, activation of PKC 
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leads to enhanced virus production in vitro (Hoffmann et al, 2008). In their study 
investigating the role of PKCβII in endocytic trafficking, Sieczkarski and colleagues 
showed that chemical inhibition of PKC by Gö6976 and calphostin C could prevent 
influenza virus entry (Sieczkarski et al, 2003). Moreover, another specific PKC 
inhibitor bisindolylmaleimide I prevented replication of influenza virus types A and B 
in vitro (Root et al, 2000). Treatment with bisindolylmaleimide I at a micromolar 
concentration reduced virus yields by more than 3 orders of magnitude.  
Inhibition of the NF-κB pathway has resulted in blockade of vRNP export (Mazur 
et al, 2007). The authors demonstrated the acetylsalicylic acid could exert an antiviral 
effect against several influenza viruses, including H5N1, in vitro and in vivo (H7N7 in 
mice). Acetylsalicylic acid (Aspirin™) (Table 11) is an FDA-approved analgesic and 
anti-inflammatory drug inhibiting cyclooxygenase (COX)-1/-2. Moreover, the 
acetylsalicylic acid blocks the IκB kinase (IKK) complex and therefore the 
phosphorylation-induced degradation of IκB. Survival rates of mice infected with 
influenza were significantly increased when acetylsalicylic acid and other NF-κB-
inhibiting agents such as the radical scavenger pyrrolidine dithiocarbamate (PDTC) and 
a proteasome inhibitor MG132 were applied as an aerosol (Mazur et al, 2007). Other 
NF-κB inhibitors, BAY11-7085 and BAY11-7082, were also able to block influenza 
virus infection (Nimmerjahn et al, 2004). Recently, another NF-κB inhibitor, SC75741, 
was shown to prevent influenza virus propagation and to protect mice against highly 
pathogenic avian influenza A (H5N1 and H7N7) viruses in vivo (Ehrhardt et al, 2013; 
Haasbach et al, 2013b).  
Proteasome inhibitors stabilizing IκB suppress of activation of the NF-κB 
signaling pathway (Haasbach et al, 2011; Russo et al, 2010; Widjaja et al, 2010). 
MG132 (Table 11) is a natural triterpene derived from a Chinese medicinal plant which 
binds to the active site of 20S proteasome to inhibit the proteolytic activity of the 26S 
proteasome complex (Guo & Peng, 2013). MG132 is widely used in basic research, but 
is not undergoing clinical development. Widjaja and colleagues showed that synthesis 
of viral RNAs depends on an ubiquitin-proteasome system, and that inhibition of 
proteasome activity by MG132 could modify virus replication at a post-fusion step 
(Widjaja et al, 2010). Another 26S proteasome inhibitor, PS-341 (Bortezomib, 
Velcade®), an FDA approved drug for treatment of multiple myeloma and several solid 
tumor types, could potently inhibit replication of influenza A virus and vesicular 
stomatitis virus (Dudek et al, 2010). The authors claimed that treatment of infected cells 
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with PS-341 resulted in induction of IκB degradation and activation of NF-κB and 
JNK/AP-1. Thus, PS-341 blocked influenza virus replication by inducing an antiviral 
state mediated by the NF-κB-dependent expression of antiviral gene products (Dudek et 
al, 2010). VL-01 (Virologik) is a member of a new class of proteasome inhibitors, 
which have been demonstrated to inhibit the replication of different influenza (H1N1 
and H5N1) strains both in vitro and in vivo (Haasbach et al, 2011). Mice treated with 
VL-01 exhibited a reduced production of proinflammatory cytokines such as IL-1α/β, 
IL-6, MIP-1β, CCL5 (C-C motif chemokine 5; also RANTES) and TNF-α induced by 
avian influenza A (H5N1) virus (Haasbach et al, 2011). 
Table 11. Selected inhibitors of signaling pathways and their antiviral activity against influenza 
virus infection. 
Name Chemical structure Target EC50 Clinical 
development 
LY294002 
 
PI3K n.a. Not in clinical 
development 
Wortmannin 
 
PI3K n.a. Not in clinical 
development 
Naphthalimide 
 
mTORC1 31 mM
a
 Not in clinical 
development 
Sirolimus 
(rapamycin) 
 
mTORC1 n.a. Approved as 
immunosuppressant 
drug 
Rottlerin 
 
PKC n.a. Not in clinical 
development 
Gö6976 
 
PKC n.a. Not in clinical 
development 
Acetylsalicylic 
acid (Aspirin™) 
 
NF-κB n.a. Approved as anti-
inflammatory drug 
Calphostin C 
 
PKC n.a. Not in clinical 
development 
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Bisindolylma-
leimide I 
 
PKC n.a. Not in clinical 
development 
BAY11-7085 
 
NF-κB n.a. Not in clinical 
development 
SC75741  
 
NF-κB 53 nMb*  Not in clinical 
development 
MG132 
 
26 S 
proteasome  
n.a. Not in clinical 
development 
PS-341 
(Bortezomib, 
Velcade®) 
 
26 S 
proteasome 
n.a. Approved for cancer 
treatment 
VL-01 
(Virologik) 
 
20S and 
26S 
proteasome 
0.8 - 2.4 
µMc 
Not in clinical 
development 
U0126 
 
MEK 1.2 - 82 
µMd* 
Not in clinical 
development 
PD-0325901  
 
MEK 5 nM
e
* Phase II against 
cancer. Stopped in 
2008. 
AZD-6244 
(Selumetinib) 
 
MEK 750 nM
e
* Phase II against 
cancer 
AZD-8330  
 
MEK 40 nM
e
* Phase I against 
cancer 
RDEA-119 
(BAY 869766) 
 
MEK 60 nM
e
* Phase I/II against 
cancer 
* values obtained on A549 cells; a (Mata et al, 2011); b (Haasbach et al, 2013b); c (Haasbach et al, 2011); 
d (Droebner et al, 2011); e (Haasbach et al, 2013a); n.a., not available.  
There are several studies demonstrating that chemical inhibition of mitogen-
activated protein kinase (MAPK) kinases (MEK) by U0126 (Table 11) can exert 
antiviral activity against influenza A (H1N1, H5N1, and H7N7) and B viruses in vitro 
and in vivo (Droebner et al, 2011; Ludwig et al, 2004; Pleschka et al, 2001). In one 
study, inhibition of MEK resulted in nuclear retention of vRNP at a late stage of virus 
replication cycle (Pleschka et al, 2001). U0126 is a highly selective inhibitor of both 
MEK1 and MEK2 with IC50 values of 72 nM and 58 nM, respectively. Due to 
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unfavourable pharmaceutical properties, U0126 did not proceed to clinical evaluation 
for cancer therapy and was examined only in research (Fremin & Meloche, 2010). A 
recent study demonstrated that four orally available MEK inhibitors, PD-0325901, 
AZD-6244, AZD-8330 and RDEA-119 (Table 11), possessed antiviral effects against 
influenza A (H1N1)pdm09 in vitro with EC50 values in nanomolar range (Haasbach et 
al, 2013a). Moreover, a combination of these inhibitors and oseltamivir has been shown 
to induce a strong synergistic antiviral effect against influenza. However, further 
investigations of the best compound combinations are needed (Haasbach et al, 2013a). 
It would be interesting to test an antiviral potential of two other MEK inhibitors, 
trametinib and PD184352, against influenza virus as single agents or in combination 
with oseltamivir. Trametinib (GSK1120212) is currently approved for the treatment of 
patients with unresectable or metastatic melanoma with V600E or V600K mutations in 
serine/threonine-protein kinase B-Raf. PD184352 (CI-1040) is available for oral 
administration and is currently being evaluated in phase II clinical trials in cancer 
patients.  
1.3.2.5. Inhibitors of lipid metabolism 
It is known that viruses also alter cellular lipid metabolism in order that they can 
achieve efficient replication. Thus it has been reported that inhibition of cholesterol and 
fatty acid biosynthesis could disturb virus replication, maturation and budding (Blanc et 
al, 2013; Munger et al, 2008; Spencer et al, 2011; Taylor et al, 2011). Munger and 
colleagues demonstrated that chemical inhibition of acetyl-CoA carboxylase and fatty 
acid synthase by TOFA (5-tetradecyloxy-2-furoic acid) and C75 (trans-4-carboxy-5-
octyl-3-methylene-butyrolactone) (Table 12), respectively, dramatically reduced 
influenza virus particle production (Munger et al, 2008). Recent studies revealed the 
role for the sterol metabolic network in the IFN-mediated antiviral response (Blanc et 
al, 2013; Liu et al, 2013b). It was shown that macrophage-synthesized and -secreted 
oxysterol, 25-hydroxycholesterol (25HC), inhibited viral growth by blocking fusion of 
virus and cell membranes (Liu et al, 2013b). In vitro 25HC blocked a broad range of 
enveloped viruses, including influenza A (H1N1), herpes simplex virus type 1 (HSV-1), 
murine gamma herpes virus 68, varicella zoster virus, HIV, Ebola, Rift Valley Fever 
Virus, Russian Spring-Summer Encephalitis, and Nipah viruses (Blanc et al, 2013; Liu 
et al, 2013b). Moreover, administration of 25HC reduces HIV infection in humanized 
mice (Liu et al, 2013b).  
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Table 12. Inhibitors of lipid metabolism and their antiviral activity against influenza virus 
infection. 
Name Chemical structure EC50 Clinical development 
TOFA 
 
n.a. Not in clinical development 
C75 
 
n.a. Not in clinical development 
25HC 
 
0.75 μMa Not in clinical development 
a (Blanc et al, 2013); n.a., not available.  
 
1.3.2.6. Inhibitors of nucleotide metabolism 
Components of the de novo pyrimidine biosynthesis pathway including one key 
enzyme, dihydroorotate dehydrogenase (DHODH), play an essential role in viral 
replication. During recent years, a number of compounds blocking the de novo 
pyrimidine biosynthesis have been described (Table 13) (Hoffmann et al, 2011; Smee et 
al, 2012; Zhang et al, 2012). Hoffmann and colleagues identified compound A3 which 
they claimed displayed broad-spectrum antiviral activity and inhibited the replication of 
influenza A and B viruses, Newcastle disease virus, human adenovirus, vesicular 
stomatitis virus, Sindbis virus (SINV), Vaccinia virus (VACV), HCV, DENV, and HIV 
in vitro (Hoffmann et al, 2011). Brequinar and NITD-982 are other inhibitors of 
DHODH that possess activity against a broad-spectrum of viruses (Qing et al, 2010). In 
the same study, the brequinar-resistant DENV was isolated. Interestingly, the brequinar-
resistant virus displayed a mutation in its NS2 gene (viral RNA polymerase). Another 
DHODH inhibitor, D282, was active against influenza A and B viruses in vitro but was 
devoid of antiviral activity in infected mice (Smee et al, 2012). Moreover, it was shown 
that leflunomide, another inhibitor of DHODH, possessed antiviral activity against HIV 
and HSV, whereas an active metabolite of leflunomide, A77-1726 (LEF-A), was active 
against polyomavirus BK and delayed mortality and improved cardiopulmonary 
functions in influenza virus-infected mice (Aeffner et al, 2012; Bernhoff et al, 2010). 
Zhang and colleagues identified a nontoxic quinoline carboxylic acid, which inhibited 
DHODH and thus blocked influenza virus infection (Zhang et al, 2012). These authors 
emphasized that pyrimidines play an essential role in the inhibition of mRNA nuclear 
export during influenza virus infection. Recently, the same authors synthesized a new 
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derivative of a quinoline carboxylic acid named C44, which was reported to inhibit 
replication of influenza virus and vesicular stomatitis virus in vitro (Das et al, 2013). 
Table 13. Inhibitors of the de novo pyrimidine biosynthesis and their antiviral activity against 
influenza virus infection. 
Name Chemical structure EC50 Clinical development 
A3 
 
0.178 μMa Not in clinical development 
D282 n.a. 6-31 μM Not in clinical development 
Leflunomide 
(AVARA®) 
 
n.a. Approved as 
immunomodulatory drug 
C44 n.a. 41 nM
b
 Not in clinical development 
 a (Hoffmann et al, 2011); b (Das et al, 2013); n.a., not available. 
 
1.4. Combination antiviral therapy 
Combination therapy, i.e. simultaneous usage of antiviral drugs with different 
mechanisms of action, is a well established approach for the treatment of rapidly 
mutating viruses such as HCV and HIV (Arts & Hazuda, 2012; Casey & Lee, 2013). 
Combination therapy is required for maximal control of virus replication and prevention 
of the emergence of drug-resistance especially in immunocompromised and seriously ill 
patients (Hayden & de Jong, 2011; Ilyushina et al, 2006; Perelson et al, 2012). 
Combination therapy might minimize the adverse effects of a single-agent therapy (De 
Clercq, 2006; Hayden, 2013). It has been shown that combination therapy is also 
effective in the treatment of influenza virus infection (Hayden et al, 1984; Ilyushina et 
al, 2006; Ilyushina et al, 2008; Nguyen et al, 2010). As early as 1984, Hayden and 
colleagues showed that human IFN-α2 in combination with rimantadine and ribavirine 
exerted a synergistic antiviral effect against influenza A (H3N2 and H1N1) and B 
viruses (Hayden et al, 1984). Exogenous IFN (alone or in combination) is approved for 
the treatment cancer as well as some chronic viral diseases (Finter et al, 1991; Rong & 
Perelson, 2010). Moreover, the feasibility and efficacy of IFN as influenza prophylaxis 
have been evaluated (Kugel et al, 2009). However, side effects after long term therapy 
and repeated administration prevented the clinical evaluation of IFNs for the treatment 
of respiratory diseases. The triple combination of amantadine, oseltamivir and ribavirin 
was shown to possess synergistic and broad-spectrum activity against drug resistant 
influenza A strains in vitro (Nguyen et al, 2010). Additionally, the triple combination 
therapy with amantadine, oseltamivir and ribavirin demonstrated good efficacy in vivo 
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(Seo et al, 2013). The effectiveness of a combination of oseltamivir and ribavirin has 
been assessed against highly pathogenic avian influenza A (H5N1) virus in vivo 
(Ilyushina et al, 2008).  
Several studies examining possible pharmacokinetic interactions between 
currently available antivirals have been performed in healthy adults (Atiee et al, 2012; 
Pukrittayakamee et al, 2011). The authors reported that drug combinations (oral 
oseltamivir combined with intravenous zanamivir therapy; oral oseltamivir combined 
with intravenous peramivir therapy) were well tolerated without causing any 
pharmacokinetic interactions.  
In addition, a number of promising antiviral agents targeting viral proteins have 
considerable potential alone or in combination with licensed antivirals. It was shown 
that favipiravir (influenza virus RNA polymerase inhibitor) combined with oseltamivir 
exerted a strong synergistic effect over monotherapy in mice infected with influenza A 
(H1N1, H3N2, and H5N1) viruses (Smee et al, 2010). In another study, the effect of 
combination therapy using favipiravir and peramivir was evaluated in a murine model 
of influenza A (H1N1)pdm09 infection (Tarbet et al, 2012). 
Additionally, inhibitors targeting components of cellular signaling pathways as 
well as other host proteins may provide better option for combination therapy in 
conjunction with already approved M2 and NA inhibitors for influenza treatment and 
prophylaxis. For example, recent in vitro studies demonstrated that a combination of 
oseltamivir with four different orally available MEK inhibitors that are currently in 
phase I/II clinical trials against cancer had antiviral activity exhibiting a strong 
synergism (Haasbach et al, 2013a). Moreover, this supports adopting a drug repurposing 
strategy to achieve the development for new antivirals. 
1.5. Drug repositioning and new formulations 
Increased knowledge of networks in virus-host interactions has opened new 
horizons for alternative drug development strategies. Drug development and 
pharmaceutical companies are already searching for new therapeutic uses of existing 
drugs or lead compounds. An increasing number of small-molecule inhibitors targeting 
host proteins or components of cellular signaling pathways are in advanced clinical 
studies or already approved for treatment of cancer, diabetes, atherosclerosis and 
cardiovascular diseases. Several recent reports have described the problems but also the 
30 
 
advantages of repurposing anticancer drugs to reveal their antiviral potential (de 
Chassey et al, 2012; Planz, 2013). In particular, current anticancer compounds are 
second-generation inhibitors, meaning that they have high specificity, better 
pharmacological properties, less side effects and are capable of oral administration. 
Most of them have safety data from phase I/II clinical trials that could be helpful in 
antiviral drug development. However, as the authors have pointed out, anticancer and 
antiviral therapies differ in dosage and duration of treatment and therefore most of the 
side effects described for cancer patients might be irrelevant for antiviral treatment. 
Therefore, more clinical data is needed. One example of successful drug repurposing is 
the FDA-approved antiprotozoal agent nitazoxanide (Alinia®), which has broad 
antiviral potency against influenza virus, HCV and rotaviruses (Kratky & Vinsova, 
2011).  
Another way to find new therapeutic uses of existing drugs is to probe alternative 
administration routes. For example, it has been demonstrated that aerosol, but not oral 
administration of acetylsalicylic acid could reduce virus titers and promote the survival 
of mice infected with influenza virus (Mazur et al, 2007).  
In the past decade, in addition to conventional oral or intravenous drug 
administration, alternative routes have been intensively studied. Micro- and 
nanomaterial- based drug delivery systems have a great potential for further application 
of drugs that do not have clinical potential due to their unfavourable bioavailability. 
There are several reports demonstrating that mesoporous materials and porous silicon 
(PSi)-based materials can be promising tools to increase dissolution and stability of 
drugs loaded within their mesopores (Salonen et al, 2008; Santos et al, 2011; Wang et 
al, 2013). These materials have a good stability and biocompatibility properties as well 
as a high drug loading capacity (Liu et al, 2013a; Wang et al, 2013). PSi nanoparticles 
loaded with anticancer agents could be additionally peptide-functionalized to achieve 
both targeted and effective cellular uptake and drug delivery (Wang et al, 2013). 
Moreover, some PSi-based materials are in widespread use in brachytherapy. For 
example, Brachysil
TM
 which is composed of 30 microne PSi particles encapsulating 
isotope [
32
P] is currently undergoing phase II clinical trials for the treatment of solid 
tumors (Salonen et al, 2008).  
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2. AIMS OF THE STUDY 
The purpose of the present study was to identify druggable host factors 
involved in influenza virus infection and to develop antiviral agents to be investigated in 
future clinical trials.  
The specific aims were: 
1. To develop a screening approach to search for druggable cellular factors involved 
in influenza virus infection; 
2. To understand the molecular mechanisms of action of promising antiviral agents 
directed against host cell factors; 
3. To begin to optimize the clinical utility of host-directed antiviral agents.  
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3. MATERIALS AND METHODS 
This chapter briefly summarizes the materials and methods used in this study. 
More detailed descriptions are found in the original publications (I - IV).  
3.1. Cells, compounds and viruses (I – IV) 
Cell types, compounds and viruses used in this study are summarized in Tables 
14, 15 and 16. All cells used in this study were cultured in the respectively 
recommended growth media and maintained at +37°C in 5% CO2. Cells were regularly 
checked by PCR to ensure they were free of mycoplasma contamination. The human 
macrophages were obtained from peripheral blood mononuclear cells (PBMCs) isolated 
from healthy individuals and buffy coats of the voluntary blood donors (Finnish Red 
Cross) by using lymphocyte separation medium (PAA) and cultured for seven days in 
Macrophage Serum-free Medium (Life Technologies) supplemented with 10 ng/ml 
human granulocyte macrophage-colony-stimulating factor (GM-CSF; Sigma-Aldrich). 
Table 14. Cells types used in the study. 
Name Description Study 
hTERT RPE  Telomerase-expressing human retinal pigment epithelial cells I - III 
MDCK Madin-Darby canine kidney cells I - IV 
A549 Human lung cancer cells I, II, IV 
VERO-E6 African green monkey kidney cells I, II 
BHK-21 Syrian hamster kidney cells I, II 
iSLK.219 Doxycycline-inducible human endothelial cells latently infected 
with Kaposi's sarcoma-associated herpes virus  
II 
Human 
macrophages 
PBMC-derived macrophages from healthy donors I, II 
NCI-H1666 Human lung cancer cells IV 
NCI-H1703 Human lung cancer cells IV 
NCI-1437 Human lung cancer cells IV 
NCI-460 Human lung cancer cells IV 
NCI-H2126 Human lung cancer cells IV 
Calu-1 Human lung cancer cells IV 
 
All compounds were dissolved in DMSO (Sigma-Aldrich) to a concentration of 
10 mM and stored at −80°C until use.  
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Table 15. Compounds used in the study. 
Name Chemical structure Molecular 
weight 
Source Study 
Obatoclax 
(GX15-070MS) 
 
413.49 Selleck Chemicals I, II, IV 
SaliPhe 
 
459.53 * I - IV 
Gemcitabine 
(Gemzar®) 
 
263.198 Selleck Chemicals I, II 
ABT-263 
(Navitoclax) 
 
974.61 Selleck Chemicals II, IV 
ABT-737 
 
813.43 Selleck Chemicals II 
ABT-199 
(GDC-0199) 
 
868.44 Active Biochem II 
MK-2206 
 
480.39 ChemieTek IV 
* provided by Professor Jef De Brabander, Department of Biochemistry, University of Texas 
Southwestern Center at Dallas, Dallas, TX, USA. 
 
The influenza A (H1N1, H3N2, and H1N1pdm09) strains were propagated in 
MDCK cells, whereas monkey Vero-E6 cells were used for propagation of A/PR8-
NS116-GFP. Virus stocks were titrated by a plaque assay on MDCK cells. The 
following virus stocks were obtained from collaborators: A/Udorn/72 from Sampsa 
Matikainen, Finland; A/Brussels/BB/2009 from Xavier Saelens, Belgium; 
B/Shandong/7/97 from Ilkka Julkunen, Finland; SINV and SFV from Tero Ahola, 
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Finland; HSV-1 and HSV-2 from Veijo Hukkanen, Finland; Bunyamwera virus 
(BUNV) from Richard M. Elliott, UK.  
Table 16. Viruses used in the study. 
Name Group Family Study 
A/WSN/33 (H1N1) (-)ssRNA Orthomyxoviridae I - IV 
A/PR/8/34 (H1N1)  (-)ssRNA Orthomyxoviridae I, III 
A/PR/8/34 (H1N1) (mouse-adapted) (-)ssRNA Orthomyxoviridae II 
A/PR8-NS116-GFP (H1N1) (-)ssRNA Orthomyxoviridae I, III 
A/Helsinki/P14/2009 (H1N1pdm09)  (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/P15/2009 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/P18/2009 (H1N1pdm09)  (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/Vi1/2009 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/Vi2/2009 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/Vi3/2009 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/543/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/629/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/551/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/628/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/552/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/568/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/604/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/668/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/598/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/526/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/678/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Helsinki/552/2013 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Brussels/BB/2009 (H1N1pdm09) (-)ssRNA Orthomyxoviridae IV 
A/Sydney/5/1997(H3N2) (-)ssRNA Orthomyxoviridae I, IV 
A/Udorn/307/1972 (H3N2) (-)ssRNA Orthomyxoviridae IV 
A/Chicken/Nigeria/BA211/2006 (H5N1) (-)ssRNA Orthomyxoviridae IV 
A/Anhui/01/2013 (H7N9) (-)ssRNA Orthomyxoviridae IV 
B/Shandong/7/97 (-)ssRNA Orthomyxoviridae I, II 
Bunyamwera virus (BUNV) (-)ssRNA Bunyaviridae I, II 
Measles virus (MeV) (-)ssRNA Paramyxoviridae I, II 
Sindbis virus (SINV) (+)ssRNA Togaviridae I, II 
Semliki forest virus (SFV) (+)ssRNA Togaviridae I, II 
Human echovirus 6 (Echo6) (+)ssRNA Picornaviridae I, II 
Tick-borne encephalitis virus (TBEV) (+)ssRNA Flaviviridae II 
Dengue virus (DENV) (+)ssRNA Flaviviridae II 
Vaccinia virus (VACV) dsDNA Poxviridae I, II 
Herpes simplex virus type 1 (HSV-1) dsDNA Herpesviridae I, II 
Herpes simplex virus type 2 (HSV-2) dsDNA Herpesviridae II 
Kaposi's sarcoma-associated herpes virus  dsDNA Herpesviridae II 
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3.2. THCPSi nanoparticles loaded with SaliPhe (III) 
In an attempt to analyze alternative options to DMSO to dissolve and deliver the 
compounds, SaliPhe was loaded into nanoparticles. The thermally hydrocarbonized PSi 
(THCPSi) nanoparticles were prepared from PSi films (III). The loading degree of 
SaliPhe in the mesopores of THCPSi nanoparticles was 2.88±0.11 wt %. The SaliPhe 
loaded nanoparticles were tested in in vitro experiments. 
3.3. In vitro experiments 
Drug screens (I, unpublished) 
Drug screens were performed in cooperation with the High Throughput 
Biomedicine Unit, FIMM Technology Centre, Finland. A 384-well plate-based assay 
was optimized to identify the compounds that could influence influenza infection. The 
toxicity assay was optimized to identify inhibitors that influence cell viability. The drug 
screens were performed against the influenza A/PR8-NS116-GFP strain in human 
hTERT RPE cells (I), and influenza A/WSN/33 and B/Shandong/7/97 viruses in A549 
cells (unpublished). Approximately, 2,500 cells were seeded in 25 µl of an appropriate 
growth using a Multidrop 384 (Thermo). After 24 h, the growth medium was changed 
to the virus growth medium. The drug library comprising either 201 compounds 
targeting host factors (I, Suppl. table 1) or a library with 337 compounds (including the 
201 drugs and the HTB compound collection (Pemovska et al, 2013)) was added to the 
cells using 10-fold serial dilutions at five different concentrations starting from 10 µM 
with an Echo acoustic dispenser (Labsite). DMSO and benzethonium chloride were 
added to the control wells. The cells were infected with influenza virus at a multiplicity 
of infection (MOI) of 3 or left uninfected (mock). At 24 h post-infection (in hTERT 
RPE cells), virus-mediated GFP fluorescence was measured using a PHERAstar FS 
plate reader (BMG Labtech). The effective concentrations (EC50) were calculated using 
SigmaPlot 11 software (Systat Software GmbH, Germany). At 24 h (in hTERT RPE 
cells) or 48h post-infection (in A549 cells), cell viability was measured using a Cell 
Titer Glo viability assay (CTG; Promega) according to the manufacturer’s instructions. 
Luminescence was read using the PHERAstar FS plate reader, and inhibitory 
concentrations (IC50) were calculated. Selectivity indices (SI=IC50/EC50) were 
calculated to distinguish the antiviral effect from toxic side effects of the compounds. 
Those compounds with SI greater than 10 were validated further. 
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Compound efficacy testing (I-IV) 
Compound efficacy testing was performed in 96-well plates with the different cell 
lines listed in Table 14. Typically, 40,000 cells were seeded in 100 µl of the appropriate 
growth medium. After 24 h, the growth medium was changed and compounds listed in 
Table 15 or SaliPhe-loaded THCPsi nanoparticles were added to the cells at 3-fold 
serial dilutions at seven different concentrations starting from 10 µM. DMSO was used 
as a control. Then, the cells were mock-infected or infected with different influenza 
strains (MOI of 3 or 10) or other viruses (Table 16). Cell viability was measured using 
the CTG assay at 24, 48 or 72 h post-infection when virus-induced cytopathic effect 
(CPE) was observed.  
Testing of compound efficacy against Kaposi's sarcoma-associated herpes virus, 
MeV, VACV, TBEV, DENV, and influenza A strains H5N1 and H7N9 infections was 
done by collaborators based on the optimized and established protocol under biosafety 
level (BSL)-2 and BSL-3 conditions (I, II, unpublished). 
Activity and toxicity scores (ATS) were calculated in order to quantitatively 
profile the compounds that rescued the infected cells (I, IV). ATS varies between -100 
and +100, where negative values indicate excessive toxicity whereas the highest 
positive values refer to the most potent compounds. Drug sensitivity scores (DSS) were 
calculated to quantitatively profile those compounds that accelerated virus-induced cell 
death (II). DSS summarizes the area under the dose-response curve relative to the total 
area between 10% threshold and 100% inhibition (Pemovska et al, 2013). 
Virus titration (I-IV) 
Antiviral efficacies of compounds (Table 15) or SaliPhe-loaded THCPsi 
nanoparticles were validated by the plaque assay. Briefly, cells were non- or compound-
treated and virus-infected (MOI of 0.1). Supernatants were collected at 24, 48 or 72 h 
post-infection. The supernatants were 10-fold diluted in virus growth media and added 
to MDCK cells on 6-well plates. After 1 h, the cells were overlaid with Avicel-based 
medium and incubated for two days. The cells were fixed with 4% formaldehyde and 
stained with crystal violet. Plaque forming units were calculated.  
For the other viruses the titration procedure slightly differed from that described 
above. SINV, SFV, VACV and BUNV were titered on Vero-E6 cells, whereas A549 
cells were used for titration of Echo6 virus. Other viruses were titered by collaborators 
based on their established protocols (I). The degree of inhibition mediated by a 
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compound was calculated as the ratio between virus titers in non- and compound-treated 
infected cells. 
Time-of-compound-addition experiment (I, II, IV) 
The cells were grown in 96-well plates and were mock- or influenza virus-
infected (MOI of 3 or 10). Compounds at non-toxic concentrations were added every 
hour. Cell viability was measured using the CTG assay at 24 h post-infection. 
Compound-competition experiment (II, IV) 
hTERT RPE or NCI-H1666 cells were grown in 96-well plates. Cells were treated 
with obatoclax (1 µM), SaliPhe (0.4 µM), gemcitabine (10 µM) or MK-2206 (10 µM) 
and with increasing concentrations of ABT-263. The cells were also treated with ABT-
263 (0.4 µM) and with increasing concentrations of obatoclax, SaliPhe, gemcitabine or 
MK-2206. Treated cells were mock- or influenza virus-infected (MOI of 3 or 10), and 
cell viability was measured using the CTG assay at 24 h post-infection. 
Caspase assay (II) 
hTERT RPE cells were grown in 96-well plates and were non- or ABT-263-
treated and mock- or influenza virus-infected or RNA transfected. At 24 h post-
infection or transfection, caspase 8, 9 and 3/7 activities were measured with Caspase-
Glo-8, -9 and -3/7 assays (Promega) according to the manufacturer’s instructions. 
Metabolic labeling of proteins with [
35
S]-Methionine 
hTERT RPE cells were grown in 96-well plates and were non- or ABT-263-
treated and mock- or influenza virus-infected (MOI of 3). At different time points post-
infection, cells were washed twice with PBS and were incubated with methionine-free 
DMEM (Sigma-Aldrich) supplemented with 10% BSA and 0.11 µCi/ml [35S]-labeled 
methionine (EasyTag EXPRESS
35
S protein labeling mix, specific activity 1175 
Ci/mmol; PerkinElmer) for 30 minutes at +37°C. Cells were washed twice with PBS 
and lysed in 2x SDS-sample buffer. Proteins were resolved by electrophoresis on 4-20% 
SDS-PAGE (BioRad) and newly synthesized [
35
S]-labeled proteins were monitored by 
autoradiography using a Typhoon 9400 scanner (Amersham). 
Fluorimetry (IV) 
The fluorescence spectra of MK-2206 were recorded (IV). 
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RNA isolation and quantitative RT-PCR (I, II, IV) 
hTERT RPE or NCI-H1666 cells were grown in 6-well plates and were non- or 
compound-treated and mock- or influenza virus-infected (MOI of 3). Total RNA was 
isolated from cells with the RNeasy Plus Mini Kit (Qiagen) and used in further 
quantitative RT-PCRs with the primers indicated in Table 17 (I, II, IV).  
Table 17. Primers used in the study 
Target 5′→3′ sequence Study 
PB2 Sequence-modifying RT: 
(+) strand: TCAGTCCCATTGCAGCCTTGCccgccgCCACG 
(-) strand: GCAGAACCCAACAGAAGAGCAAtttaTttATATTTG 
PCR: 
Fwd: GCAGAACCCAACAGAAGAGC 
Rev: TCAGTCCCATTGCAGCCT 
I, II 
β-actin Fwd: CCGACAGGATGCAGAAGG 
Rew: AGGAAAGACACCCACCTTGA 
I, II 
NS1 Fwd: GAAATGTCAMGAGACT 
Rew: AGAAAGCTCTTATCTCTTG 
IV 
huGAPDH Fwd: GGCTGGGGCTCATTTGCAGGG 
Rew: TGACCTTGGCCAGGGGTGCT 
IV 
18S Hs99999901_s1* IV 
IFN-β Hs01077958_s1* IV 
IL-29 Hs00601677_g1* IV 
* TaqMan primers and probes from Applied Biosystems. 
RNA transfection (I, II) 
In the viral RNA transfection experiment, A/WNS/33 virus was grown in MDCK 
cells. Supernatants were collected at 24 h post-infection, and the virus was pelleted 
using ultracentrifugation at 285,000 g for 4 h. Viral RNA was purified and transfected 
into hTERT RPE cells using Lipofectamine 2000 (Life Technologies) according to the 
manufacturer’s instructions. Six hours after transfection, the medium was replaced with 
growth medium with or without ABT-263. After 18 h, the cell viability and caspase 
activities were measured. 
Knockdown of the myeloid cell leukemia-1 (Mcl-1) protein was done in hTERT 
RPE cells using Hs_MCL1_12 Flexi-Tube siRNA (SI04949721; Qiagen) to suppress 
the expression of Mcl-1 (I).  
Transcription profiling (IV) 
NCI-H1666 cells were grown in 6-well plates and were non- or MK-2206-treated 
and mock- or influenza virus-infected (MOI of 3). After 8 h post-infection, the cells 
were collected, total RNA was isolated and used in the subsequent whole genome gene 
expression analysis (IV).  
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Immunoprecipitation and mass spectrometry (II) 
Bcl-xL-associated factors were immunoprecipitated from non- or ABT-263-
treated and mock- or influenza-infected hTERT RPE cells and analyzed using liquid 
chromatography-tandem mass spectrometry (II). 
Immunoblotting (I, II, IV) 
Cells were grown in 96-well plates and were non- or compound-treated and mock- 
or influenza virus-infected (MOI of 3 or 10). At different time points post-infection, the 
cells were lysed in 2x SDS-sample buffer. Proteins were resolved by electrophoresis on 
4-20% SDS-PAGE and transferred to polyvinylidine fluoride membranes (GE 
Healthcare). The membranes were blocked with 5% milk in Tris-buffered saline (TBS) 
and incubated with primary guinea pig anti-NS1, rabbit anti-M1 or rabbit anti-NP 
(1:2000, 1:2000, and 1:500 dilutions, respectively; from Ilkka Julkunen, Finland), 
mouse anti-LRP130 (1:100; clone G-10; Santa Cruz Biotechnology), rabbit anti-Bcl-xL 
(1:1000; Cell Signaling Technology), rabbit anti-Bid (1:1000; Cell Signaling 
Technology), rabbit anti-Bax (1:100; Santa Cruz Biotechnology), mouse anti-Bad 
(1:200; Santa Cruz Biotechnology), rabbit anti-UACA (1:250; Sigma-Aldrich) or mouse 
anti-β-actin (1:2000; Termo Fisher Scientific) antibody overnight at +4°C. After three 
washes, membranes were incubated for 4 h at 4°C with the representative secondary 
antibodies conjugated to infrared dyes 680LT or 800CW (1:20,000; Li-Cor 
Biosciences). The membranes were scanned with an Odyssey scanner (Li-Cor 
Biosciences).  
Immunofluorescence assay (I-IV) 
hTERT RPE or NCI-H1666 cells were grown on cover glasses in 6-well plates. 
Cells were non- or compound-treated and mock- or influenza virus-infected (MOI of 3 
or 30) on ice for 1 h. Cells were washed twice with ice-cold virus growth media, 
overlaid with pre-warmed media with or without compound, and incubated at +37°C in 
5% CO2. At 1, 2, 4 or 18h post-infection cells were fixed with 4% paraformaldehyde 
and blocked and permeabilized with PBS with 1% BSA and 0.1% Triton X-100. The 
following antibodies were used in the detection of proteins, rabbit anti-Bcl-xL (1:200; 
clone 54H6; Cell Signaling Technology), mouse anti-Bad (1:100; clone c-7; Santa Cruz 
Biotechnology), rabbit anti-Tom20 (1:300; clone FL-145; Santa Cruz Biotechnology), 
human anti-Mcl-1 (1:100; clone 22/Mcl-1; BD Transduction Laboratories) or rabbit 
anti-NP and anti-M1 (1:1000; from Ilkka Julkunen, Finland). Secondary antibodies 
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were anti-mouse or anti-rabbit Alexa Fluor 594 or anti-rabbit Alexa Fluor 488-
conjugated antibodies (1:2000 or 1:1000; Life Technologies). Nuclei were 
counterstained with DAPI. Images were captured with a Nikon 90i microscope and 
processed with NIS Elements AR software. 
Phospho-protein profiling (IV) 
NCI-H1666 cells were grown in 6-well plates and were non- or MK-2206-treated 
and mock- or influenza virus-infected (MOI of 3). After 0.5, 4 and 12 h post-infection, 
the cells were lysed and the phosphorylation profiles of 43 kinases and 2 related 
substrates were analyzed using a human phospho-kinase array (R&D Systems) 
according to the manufacturer’s instructions. The membranes were placed on films and 
were exposed to X-rays and then the films were scanned. Each image was analyzed with 
ImageJ software (NIH, USA).  
Cytokine profiling (I, II, IV) 
Cytokine profiling was performed using mouse lung homogenates or supernatants 
of non- or compound-treated and mock- or influenza virus-infected (MOI of 3 or 10) or 
vRNA-transfected cells. Cytokine levels were measured using the human or mouse 
cytokine array panel A (R&D Systems) according to the manufacturer’s instructions. 
The membranes were exposed onto X-ray films and the films were scanned. The 
scanned image was analyzed with ImageJ software. In addition, the levels of TNF-α, 
IFN-β and IFN-λ in the cell supernatants were assayed with ELISA (PBL Interferon 
Source) (I, II). 
Automated image acquisition and image analysis (IV) 
MDCK cells were grown in 96-well plates and treated with different 
concentrations of MK-2206. In a subsequent experiment, MDCK cells were treated with 
MK-2206 (10 μM), and in combinations with NH4Cl (20 mM), SaliPhe (0.4 μM) or 
obatoclax (0.4 μM). Cells were fixed with 4% paraformaldehyde and imaged with a 
modular epifluorescence microscope ScanR (Olympus) to analyze the number and the 
mean intensity of the objects (IV). 
Serial-passage experiment (IV, unpublished) 
Human NCI-H1666 cells were grown in 6-well plates and were non- or 
compound-treated (MK-2206 or SaliPhe) and infected with A/Helsinki/P14/2009 (MOI 
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of 0.1). At 48 h post-infection, 20 μl of medium was passaged to fresh cells. During 
passaging, the concentration of compounds was gradually increased (MK-2206, from 
0.1 to 10 μM; SaliPhe, from 0.01 to 1 µM). A total of 15 passages were performed and 
the virus titers were determined with plaque assay. 
3.4. In vivo experiments 
Compound efficacy testing in vivo (II) 
Pathogen-free 6-7-week old female BALB/c mice were used for ABT-263 
efficacy testing in vivo. Mice were inoculated intranasally with 50 µl PBS with or 
without two median lethal doses (LD50) of the mouse-adapted influenza A/PR8/8/34 
strain. ABT-263 (50 mg/kg in carrier) was administered orally, and then the mice were 
monitored for 14 days for weight loss (II). Mice were sacrificed on day 6 and lung 
tissue dissected. Virus titers, caspase 3/7 activities and cytokine levels were measured 
from lungs (II).  
Histochemistry (II) 
In the experiment monitoring the degree of inflammation, the left lobes of the 
mouse lung slices were processed for histochemistry and the tissue slides were stained 
with hematoxylin and eosin (II). 
3.5. Ethics 
Virus experiments were carried out under BSL-2+ conditions and in compliance 
with regulations of the University of Helsinki (permit 21/M/09) and under BSL-3 
conditions and in compliance with regulations of the Centre de Recherche Public de la 
Sante/Laboratoire National de Santé. Mouse influenza virus infection experiments were 
carried out in the Ghent University under BSL-2+ conditions and were authorized by 
the Institutional Ethics Committee on Experimental Animal of the VIB Department for 
Molecular Biomedical Research of Ghent University. Buffy coat preparations of 
voluntary blood donors were obtained with permission from the Finnish Red Cross 
Blood Transfusion Service and their use was approved by the ethics review committee 
of the University of Helsinki Central Hospital, Finland (165/13/03/00/2011). Collection 
of blood samples from volunteers was approved by the ethics review committee of the 
University of Helsinki Central Hospital, Finland (244/13/03/01/2012).  
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4. RESULTS AND DISCUSSION 
4.1. Identification of host factors involved in influenza virus replication 
4.1.1. Assembly of library of compounds targeting host factors (I, II, IV) 
There are two main systemic approaches which can be used when searching of 
host factors essential for virus replication. One approach is to conduct a genome-wide 
siRNA screening to identify the host genes that are crucial for virus replication (Karlas 
et al, 2010; Konig et al, 2010; Li et al, 2009; Sessions et al, 2009). The other approach 
is screening of libraries of chemical compounds capable of blocking host factors for 
molecules that inhibit virus replication without evoking toxicity in the host cell (Zhang 
et al, 2012). Both approaches are widely used for understanding viral biology as well as 
developing alternative antiviral drugs. 
To identify host factors essential for influenza virus replication it was decided to 
assemble a library of small-molecule inhibitors targeting cellular proteins and 
components of signaling pathways. The primary focus was on commercially available 
drugs with well described targets that were approved or under clinical development for 
treatment of cancer or other diseases. Small-molecule inhibitors that target the cell cycle 
control, apoptotic pathways, lipid metabolism, and other cellular functions that could be 
essential for influenza infection in the host cell were included. Moreover, the screen 
also contained some small-molecule inhibitors with known anti-influenza activity such 
as gemfibrozil and TOFA (lipid metabolism), 17-AAG and bortezomib (protein quality 
control), fluorouracil and cytarabine (de novo nucleotide biosynthesis), 3-methyladenine 
(autophagy), PD153035 (EGFR) and wortmannin (PI3K) (Chase et al, 2008; Dudek et 
al, 2010; Eierhoff et al, 2010; Meneghesso et al, 2012; Müller et al, 2012; Munger et al, 
2008; Zhou et al, 2009). In addition, functional analogues of known influenza 
inhibitors, such as erlotinib and gefitinib (analogues of PD153035), 17-DMAG (analog 
of 17-AAG), carfilzomib (analog of bortezomib), and leflunomide and gemcitabine 
(analogues of fluorouracil) were examined. The control was a v-ATPase inhibitor, 
SaliPhe, which was shown to block influenza virus replication in vitro and in vivo 
(Müller et al, 2011). A total of 201 small-molecule inhibitors were collected into the 
library (I, Suppl. table 1). Since most of these inhibitors are approved or are under 
clinical development for treatment of human malignancies, it was decided to screen the 
library in nonmalignant cells in order to avoid cancer-specific effects of drugs. A human 
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telomerase-expressing retinal pigment epithelial (hTERT RPE) cell line was selected 
since this line has been shown to be appropriate for influenza A virus replication 
(Michaelis et al, 2009). Additionally, two specific drug subsets were assembled 
targeting the anti-apoptotic signals, especially the Akt kinase and the B-cell lymphoma 
2 (Bcl-2) family members. It is well established that influenza virus activates the 
PI3K/Akt/mTOR signaling pathway for efficient viral replication (Ehrhardt et al, 2006; 
Zhirnov & Klenk, 2007). However, none of Akt inhibitors had been tested in influenza 
virus-infected cells. Therefore, the first set to be examined contained inhibitors targeting 
Akt such as MK-2206, Akt inhibitor VIII, GDC-0068, and perifosine (IV). The second 
set consisted of ABT-263, ABT-737 and ABT-199, gossypol and TW-37 that target 
predominantly Bcl-2, B-cell lymphoma-extra large (Bcl-xL), and Bcl-2-like protein 2 
(Bcl-w) proteins (II). It was hypothesized that chemical inhibition of Bcl-xL, Bcl-2 and 
Bcl-w could have an effect on the survival of virus-infected cells. 
Our library and the drug subsets comprised highly specific small-molecule 
inhibitors targeting several well-described host factors and components of signaling 
pathways. The evaluation of this library and the subsets against influenza virus infection 
could provide information about the importance of these host factors both for virus 
infection and for cell survival. Moreover, this library and subsets could be tested against 
other virus infections to clarify the broad-spectrum antiviral properties of those 
compounds. Additionally, since the library included multiple drugs that are approved or 
are under clinical development for treatment of cancer or other diseases, it was deemed 
to verify the potential of these drugs for repositioning as antiviral agents. 
4.1.2. Method for searching potential antiviral agents (I, II, IV) 
After assembly of the library and the drug subsets a cell-based approach was 
developed which allowed identification of chemical probes to study virus-host 
interactions. In this method, increasing concentrations of small-molecule inhibitors were 
tested for their ability (i) to attenuate or accelerate death of infected cells, and (ii) to 
suppress or induce virus replication at concentrations that would not be toxic for 
noninfected cells (mock control). Cell survival and virus replication were measured by 
cell viability and plaque assays, respectively. Importantly, these techniques are suitable 
for virus infections that result in virus-induced CPE. In order to obtain high CPE values, 
MOI of 3 or higher was used. This approach was successfully used and its validity 
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confirmed against different influenza strains and other viruses in different BSL-2 and 
BSL-3 laboratories (I, II, unpublished). 
4.1.3. Identification of hit compounds (I, II, IV) 
The library or the subsets of Akt or Bcl-2 inhibitors was screened against the 
influenza A/PR8-NS116-GFP strain in hTERT RPE cells (I, fig. 1A), 
A/Helsinki/P14/2009 in MDCK cells (IV, fig. 1B), and A/WSN/33 in human PBMC-
derived macrophages (II, Suppl. fig. 1B). Influenza A/PR8-NS116-GFP strain expresses 
the NS11–116-GFP fusion protein which means that it is possible to monitor the antiviral 
efficacy of the compounds by measuring virus-mediated GFP fluorescence and i.e. it 
can identify those compounds that target different stages of influenza infection ranging 
from virus attachment to viral protein synthesis and quality control. Compound 
cytotoxicity tests were performed in parallel. The screen revealed that obatoclax, 
SaliPhe and gemcitabine markedly attenuated virus-mediated GFP expression in a dose-
dependent manner and promoted survival of influenza virus-infected cells (I, fig. 1B). 
The antiviral activities of these compounds are summarized in Table 18. Moreover, 
obatoclax, gemcitabine and SaliPhe significantly reduced virus production in hTERT 
RPE cells by more than 3 orders of magnitude (I, fig. 2B).  
Table 18. Identified compounds and their antiviral activity against the influenza A/PR8-NS116-
GFP strain. 
Name Cellular target EC50 Clinical development 
Obatoclax 
(GX15-070MS) 
Mcl-1, Bcl-2, Bcl-xL 0.014 µM Phase I/II against cancer 
SaliPhe v-ATPase 0.254 µM Not in clinical development 
Gemcitabine 
(Gemzar®) 
Ribonucleotide reductase 0.068 µM Approved for cancer 
treatment 
MK-2206 Akt n.a. Phase I/II against cancer 
ABT-263 
(Navitoclax) 
Bcl-xL, Bcl-2, Bcl-w 0.106 µM Phase I/II against cancer 
ABT-737 Bcl-xL, Bcl-2, Bcl-w n.a. Phase II against cancer 
ABT-199 
(GDC-0199) 
Bcl-2 n.a. Phase II against cancer 
n.a., not available. 
When testing antiviral effects of the subset of Akt inhibitors it was found that MK-2206 
rescued MDCK cells infected with the influenza A(H1N1)pdm09 strain (IV, fig. 1B). 
None of the other Akt inhibitors demonstrated antiviral effect. It was found that ABT-
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263 and its structural analogues ABT-737 and ABT-199 induced apoptosis in influenza 
virus-infected cells in a dose-dependent manner (II, Suppl. fig. 1). In contrast, gossypol 
and TW-37 exerted no effect on the survival of influenza virus-infected cells. A non-
toxic concentration of ABT-263 was then selected and the survival of mock- or 
influenza virus-infected cells was monitored at different time points post-infection. The 
results revealed that ABT-263 promoted premature apoptosis in influenza virus-infected 
cells and interfered with virus replication (II, fig. 1). Additionally, the apoptotic cell 
death was dependent on MOI. 
Thus, two different sets of compounds were identified: (i) obatoclax, SaliPhe, 
gemcitabine and MK-2206 that rescued influenza virus-infected cells and reduced virus 
production, and (ii) ABT-263, ABT-737 and ABT-199 that promoted premature 
apoptosis in influenza virus-infected cells and also reduced virus titers. Obatoclax 
(GX15-070) is a BH3 mimetic which inhibits Mcl-1 in addition to blocking Bcl-2 and 
Bcl-xL (Nguyen et al, 2007). Obatoclax overcomes Mcl-1-mediated resistance to 
apoptosis and currently is in phase I/II trials for the treatment of chronic lymphocytic 
leukemia. SaliPhe is an investigational anticancer and anti-influenza compound, which 
has been reported to inhibit v-ATPase activity (Lebreton et al, 2008; Müller et al, 2011). 
Gemcitabine (Gemzar®) is a nucleoside analog, which is FDA approved for cancer 
treatment. There is a report that gemcitabine blocks cellular ribonucleotide reductase 
required for DNA replication and repair (Cerqueira et al, 2007). MK-2206 is a potent, 
oral allosteric inhibitor of Akt kinases, which inhibits auto-phosphorylation of both Akt 
T308 and S473 (Hirai et al, 2010). Currently MK-2206 is in phase I/II trials for cancer 
treatment. The two BH3 mimetics, ABT-263 (Navitoclax) and ABT-737, target the anti-
apoptotic proteins Bcl-xL, Bcl-2 and Bcl-w but not Mcl-1 or A1 (Tse et al, 2008). A 
recently discovered BH3 mimetic, ABT-199 (GDC-0199), has been claimed to 
selectively inhibit Bcl-2 but not Bcl-xL (Vandenberg & Cory, 2013; Vogler et al, 2013). 
Currently ABT-263 and its structural analogues are undergoing phase I/II trials for the 
treatment of chronic lymphocytic leukemia.  
Taken together, these results suggest that cellular v-ATPase, Akt kinase, 
ribonucleotide reductase and anti-apoptotic Bcl-2 family members, such as Mcl-1, Bcl-
xL, Bcl-2 and Bcl-w, represent essential host factors for influenza virus infection. 
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4.2. Potential mechanisms of action of promising compounds (I, II, IV) 
The mechanism of action of obatoclax, SaliPhe, gemcitabine, MK-2206 and ABT-
263 was investigated by testing these inhibitors in a time-of-compound-addition 
experiment. Appropriate cells were infected with influenza virus, and the inhibitors 
were added every hour. It was found that obatoclax, SaliPhe and MK-2206 added at the 
time of infection could inhibit early steps of influenza virus infection (I, fig. 3A; IV, fig. 
2D). It has been shown previously that SaliPhe inhibited v-ATPase that is needed for 
acidification of endosomes and release of vRNPs into the cytoplasm (Müller et al, 
2011). Thus, one could postulate that obatoclax and MK-2206 also inhibit entry stages 
of influenza virus infection, whereas gemcitabine which targets cellular ribonucleotide 
reductase blocks influenza virus at the stage of viral RNA transcription and replication. 
Interestingly, ABT-263 induced apoptosis in influenza virus-infected cells 
independently of the time of its addition (II, fig. 3C). To address the stage of influenza 
virus infection when ABT-263 triggers the cell death a compound competition 
experiment was conducted with obatoclax, SaliPhe, gemcitabine and MK-2206. It was 
found that obatoclax, SaliPhe and MK-2206, but not gemcitabine, rescued ABT-263-
treated cells from influenza virus-mediated death (II, fig. 3A and B; IV, fig. 2E). These 
results indicate that ABT-263 sensitized cells to undergo premature apoptosis at 
multiple stages of influenza virus infection following viral endocytic uptake.  
Viral NP or M1 proteins were then monitored in an immunofluorescence assay at 
different time points. Immunofluorescence experiments revealed that obatoclax, SaliPhe 
and MK-2206 prevented accumulation of NP in the nucleus or M1 in the cytoplasm 
compared to non-treated or gemcitabine-treated influenza virus-infected cells (I, fig. 
3B; IV, fig. 4G and H).  
Next the production of viral RNAs and the synthesis of viral proteins were 
compared at different time points post-infection. The results demonstrated that 
obatoclax, SaliPhe, gemcitabine and MK-2206 substantially affected viral RNA 
transcription and replication and subsequent synthesis of viral proteins (I, fig. 3C and D; 
IV, fig. 2F). Since ABT-263 was able to induce premature apoptosis in influenza virus-
infected cells already at 8 h post-infection, production of viral RNAs and proteins 
declined at the same time (II, Suppl. fig. 3).  
Based on these results it was concluded that obatoclax, SaliPhe and MK-2206 
block virus entry at a stage preceding vRNA uncoating, while ABT-263 sensitizes the 
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release of vRNPs from the endosome to the cytoplasm, and gemcitabine inhibits 
transcription of viral RNAs (summarized in Figure 5). Thus, host factors such as Mcl-1, 
v-ATPase and Akt kinase are necessary for endocytic trafficking and release of vRNPs 
into the cytoplasm, while Bcl-xL, Bcl-2 and Bcl-w sensitize the cell to viral RNA after 
virus release from the endosome, and ribonucleotide reductase is essential for viral 
RNA transcription and replication in the nucleus of the infected cell. 
 
Figure 5. Schematic representation showing the stages of influenza virus replication cycle that 
could be blocked by obatoclax, SaliPhe, gemcitabine, MK-2206 or accelerated by ABT-263 and 
its structural analogues. Compounds marked with green rescue infected cells; those marked with 
red accelerate virus-induced apoptosis. 
 
Obatoclax is a novel anti-influenza agent, whereas SaliPhe and gemcitabine 
analogues have been shown to possess antiviral activity (Meneghesso et al, 2012; 
Müller et al, 2011). Recently MK-2206 was demonstrated to exert an antiviral effect 
against HSV in vitro (Cheshenko et al, 2013). In order to prove that obatoclax target 
Mcl-1 is an essential host factor for influenza virus infection Mcl-1 was partially 
silenced in hTERT RPE cells by Mcl-1-specific siRNA and these cells were infected 
with the influenza A/PR8-NS116-GFP strain. At 24 h post-infection, the levels of 
influenza virus-mediated GFP expression and cell viability were analyzed. The results 
revealed that silencing of Mcl-1 substantially reduced influenza virus-mediated GFP 
expression and slightly affected the viability of the infected cells (I, fig. 4B). Taken 
together, these data suggest that cellular Mcl-1 is involved in both influenza virus 
infection and cellular apoptosis. In addition, it was demonstrated that Mcl-1 is 
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upregulated during the first hours of influenza virus infection (I, fig. 4C). Data from the 
immunofluorescence experiment revealed that Mcl-1 has a localization pattern similar 
to that of viral M1 (I, fig. 4D), indicating that Mcl-1 could be involved in virus 
recognition. 
It has been shown that ABT-263 targets Bcl-xL, Bcl-2 and Bcl-w proteins at 
mitochondria in the cytoplasm and disrupts their interactions with Bcl-2 antagonist of 
cell death (Bad), Bcl-2-associated X protein (Bax) and Bcl-2 antagonist killer (Bak) 
proteins to initiate apoptosis in cancer cells (Tse et al, 2008). It was tested whether 
ABT-263 could exert these interactions in nonmalignant human cells infected with 
influenza virus. The immunofluorescence and immunoprecipitation (IP) experiments 
revealed that at non-toxic concentrations ABT-263 displaced Bad from Bcl-xL and 
mitochondria, and influenza virus facilitated this process (II, fig. 4 and 5).  
Interactions of Bcl-xL, Bcl-2 and Bcl-w proteins are not limited to Bad, Bax and 
Bak. Bcl-xL has also been shown to interact with VDAC, Bim, DMN1L, Becn1, 
PGAM5, PUMA, p53, IKZF3, HEBP2, whereas Bcl-2 also interacts with APAF1 
(apoptotic protease-activated factor 1), BBC3, BNIPL, MRPL41, TP53BP2, FKBP8, 
BAG1, RAF1, EGLN3 and G0S2 (Follis et al, 2013; Renault & Chipuk, 2013). In 
addition, the composition of Bcl-xL/Bcl-2 interactions could differ in different cell 
types. Based on IP and mass-spectrometry data it was confirmed that in hTERT RPE 
cells Bcl-xL could interact with Bad, Bax and Bak and also it was found to have novel 
interacting partners, such as UACA (uveal autoantigen with coiled-coil domains and 
ankyrin repeats), FLII (protein flightless-1 homologue), LRRFIP2 (leucine-rich repeat 
flightless-interacting protein 2), TOLLIP (Toll-interacting protein), TRIM21, H2B 
(histone H2B), DHX9 (ATP-dependent RNA helicase A), 14-3-3, PAWR, NUAK1, 
DAPK1, various cytoskeleton proteins and viral HA, M1, NS1, NP proteins (II, Suppl. 
table 1). The Bcl-xL interactions with pattern recognition receptors, such as LRRFIP2, 
H2B and DHX9, indicate that Bcl-xL is potentially involved in the sensing of viral 
nucleic acids, and the Bcl-xL interactions with FLII, TOLLIP and LRRFIP2 indicate 
that it could be also involved in TLR4 (Toll-like receptor 4) signaling cascade. Thus, 
novel interacting partners for Bcl-xL, and possibly for Bcl-2 and Bcl-w, were 
investigated. 
The disruption of Bcl-xL, Bcl-2 and Bcl-w interactions with newly identified 
partners might contribute to ABT-263-mediated death of infected cells. It was examined 
whether ABT-263 had any effect on the interactions between Bcl-xL and its newly 
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identified protein partners in mock- and influenza virus-infected cells. SDS-PAGE 
analysis of immunoprecipitated Bcl-xL-interacting proteins detected differences in 
protein composition of IPs (II, fig. 5B). Mass-spectrometry and immunoblot analysis of 
protein candidates showed that ABT-263 in combination with influenza virus could 
displace UACA, Bax and Bad from Bcl-xL (II, fig. 5A and B). Thus, it is concluded 
that ABT-263 alters the composition of Bcl-xL, and perhaps Bcl-2 and Bcl-w, 
interactions in influenza virus-infected cells. 
Since Bcl-2 proteins regulate apoptosis, the activation of caspase-8, -9, and -3/7 in 
response to ABT-263 treatment and influenza virus infection was monitored in hTERT 
RPE cells. It is well known that apoptosis can be activated by extrinsic and intrinsic 
stimuli that lead to activation of caspase cascades. Extrinsic stimuli activate pro-
caspase-8, which in turn activates pro-caspase-3. The intrinsic pathway (also known as 
the mitochondrial pathway) is triggered when Bax is relocated to the mitochondria 
leading to cytochrome c release. Cytosolic cytochrome c interacts with APAF1 which 
activates pro-caspase-9 and pro-caspase-3. Caspase-3 is the terminal enzyme in both 
extrinsic and intrinsic pathways (Cullen & Martin, 2009).  
It was observed that a combination of ABT-263 and influenza virus infection 
resulted in enhancement of caspase-8, -9, -3 and -7 activities, and this phenomenon 
coincided with the decline of cell viability (II, fig. 6A and B). In influenza virus-
infected cells activated caspases cleaved their substrates, such as Bid, and disrupted 
basic cellular pathways and functions, that resulted in inhibition of transcription and 
translation of cellular and viral mRNAs and reduction in production of infectious 
virions (II, Suppl. fig. 3). Thus, ABT-263 is able to modulate Bcl-xL, and perhaps Bcl-
2 and Bcl-w interactions, and this activates caspase-8, -9 and -3/7 to trigger apoptosis in 
influenza virus-infected cells. Interestingly, in hTERT RPE cells transfected with 
influenza virus genomic RNA, ABT-263 was also able to stimulate caspase-9 and -3/7 
activity and weakly caspase-8 (II, fig. 6C). However, the latter effect was insufficient to 
trigger cell death (II, fig. 6D). Thus, these results indicate that ABT-263 promotes 
premature apoptosis only in response to replicating virus. 
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4.3. Effect of compounds on influenza virus-mediated cellular antiviral 
and pro-inflammatory responses (I, II, IV) 
The innate immune response is crucial in antiviral defence and is associated with 
production of cytokines by the infected cell; the immune response is important in 
intercellular signaling and communication. The cytokines are a diverse group of small 
proteins which include interferons (IFN-α, IFN-β, IFN-γ, and IFN-λ), interleukins (e.g. 
IL-1α, IL-1β, IL-18), chemokines (about 44 members), colony-stimulating factors 
(CSF; GM-CSF, G-CSF) and TNF (Tisoncik et al, 2012). The cytokines are responsible 
for development of pro-inflammatory (IL-1, TNF, IL-6 and IL-12) and anti-
inflammatory (IL-10, IL-4 and TNF-β) responses in virus-infected and in neighboring 
cells. Several studies have described a number of drugs that could reduce the production 
of pro-inflammatory cytokines, and thus these compounds could potentially be used for 
influenza treatment either on their own or in combination with licensed antivirals. For 
instance, gemfibrozil has been shown to inhibit the production of pro-inflammatory 
cytokines and to increase the survival of mice infected with influenza A (H2N2) virus 
(Budd et al, 2007). Combinations of zanamivir and inhibitors of inflammation, such as 
celexoxib and mesalasine, also increased the survival of mice infected with influenza A 
(H5N2) virus (Carey et al, 2010). 
The next question asked was whether the identified inhibitors could suppress 
influenza virus-mediated antiviral and pro-inflammatory responses. It was found that 
obatoclax, SaliPhe and gemcitabine suppressed influenza virus-mediated production of 
pro-inflammatory cytokines including IP-10 (IFN-γ-induced protein 10; also CXCL10), 
CXCL1 (C-X-C motif chemokine 1; also GROα), IL-6, IL-8, CCL2 (also MCP-1), and 
CCL5 (also RANTES) (I, fig 5). Surprisingly, obatoclax inhibited, whereas SaliPhe and 
gemcitabine stimulated, the production of antiviral IFN-β and IFN-λ. These results 
indicate that obatoclax, in contrast to SaliPhe and gemcitabine, could prevent activation 
of cellular antiviral responses, most probably, via suppression on the Mcl-1-type I IFN 
signaling axis.  
The effect of MK-2206 on cellular signaling pathways was also investigated. 
Phospho-proteome profiling revealed that MK-2206 treatment abrogated influenza 
virus-mediated decrease phosphorylation of Akt (T308), HSP60 and p53 (S392), and 
increase phosphorylation of Akt (S473), HSP27 (S78/S82), and c-Jun (S63) at 12 h 
post-infection (IV, fig. 4B). A whole-genome expression analysis and cytokine/ 
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chemokine profiling showed that MK-2206 reduced influenza virus-mediated 
transcription of 23 out of 70 antiviral and pro-inflammatory genes (log fold change cut 
off > 2 and < -2; IV, fig. 5) and production of cytokines, including IP-10 (also 
CXCL10), IL-6, IL-8, GM-SCF (granulocyte-macrophage colony-stimulating factor; 
also CSF-2), IL-1α, IL-1ra (interleukin-1 receptor antagonist), and CCL5 (IV, fig. 6). 
Thus, MK-2206 prevents the development of cellular immune responses in influenza 
virus-infected cells. It is essential to note, that MK-2206 regulates expression of LPIN1, 
RASD1, DHCR7, HMGCR, SC4MOL, HMGCS1, SQLE, and ABCA1 genes (log fold 
change cut off > 1 and < -1) involved in lipid biosynthesis pathways. Thus, MK-2206 
could modulate lipid metabolism. 
The analysis of cytokine production in ABT-263 treated cells revealed that ABT-
263 attenuated the influenza virus-mediated production of IP-10, IL-6, IL-8, CXCL1, 
CCL2, CCL5, IFN-β and IFN-λ, but stimulated the production of IL-1ra. Similar results 
were obtained with ABT-737 and ABT-199 (II, Suppl. fig. 4). Interestingly, ABT-263 
treatment was ineffective in inhibition of CCL5, IL-6, IL-8, IFN-β and IFN-λ 
production in cells transfected with influenza virus genomic RNAs. Thus, it is 
concluded that ABT-263 induces premature apoptosis which limits the development of 
cellular antiviral and pro-inflammatory responses. Importantly, ABT-263 lowered the 
survival rate of influenza virus-infected mice by disrupting the host innate response (II, 
fig. 7). It is proposed that the imbalance likely resulted from an inability of the immune 
system to clear the virus, eventually leading to the death of the influenza virus-infected 
and ABT-263-treated mice. Therefore, ABT-263 was excluded from further studies. 
4.4. Spectrum of antiviral activities of compounds (I, IV, unpublished) 
Since different viruses use the same host factors for efficient replication, 
development of host-directed antivirals with broad-spectrum potential is a very 
promising strategy. For instance, it has been demonstrated that the protease inhibitors 
camostat, nafamostat, gabexate and aprotinin are active against negative-stranded RNA 
viruses including influenza types A and B, MeV, respiratory syncytial virus and 
parainfluenza virus type 3 (Hosoya et al, 1992). Moreover, the sterol metabolite 25HC 
was reported to inhibit a broad range of enveloped RNA and DNA viruses by blocking 
the membrane fusion between the virus and the cell (Liu et al, 2013b).  
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The possibility that Mcl-1, v-ATPase, ribonucleotide reductase and Akt could be 
antiviral targets for a broad range of influenza viruses was tested by examining the 
effects of obatoclax, SaliPhe, gemcitabine and MK-2206 against influenza A (H3N1, 
H1N1, H1N1pdm09, H5N1, and H7N9) and B viruses (I, IV). The results which are 
summarized in Table 19 indicate that obatoclax and SaliPhe do exert antiviral activity 
against a broad range of influenza A and B viruses (I, table 1), while MK-2206 
predominantly inhibits replication of influenza A(H1N1)pdm09 viruses as well as 
A/WSN/33(H1N1) at high concentrations (IV, fig. 3A and B). Gemcitabine activity 
could be limited to certain influenza strains. Moreover, it was found that obatoclax and 
SaliPhe exhibited antiviral activity in different cell types, whereas gemcitabine activity 
was cell-type specific (I, Suppl. fig. 1).  
Table 19. Viruses tested in vitro for their susceptibility to selected inhibitors. 
Virus name Obatoclax SaliPhe Gemcitabine MK-2206 
A/WSN/33(H1N1) + + + + 
A/PR/8/34 (H1N1)  + + + – 
A/Helsinki/P14/2009 
(H1N1pdm09)  
n.a. + n.a.   +* 
A/Udorn/307/1972 (H3N2) n.a. + n.a. – 
A/Sydney/5/1997(H3N2)  + + + – 
A/Chicken/Nigeria/BA211/2006 
(H5N1) 
+ + – – 
A/Anhui/01/2013 (H7N9) + – – – 
B/Shandong/7/97 + + + – 
BUNV + + – + 
MeV  – – – n.a. 
SINV + + + n.a. 
SFV      +**     +** + – 
Echo6 + – + - 
VACV – – – n.a. 
HSV-1  – – + – 
“+” possess antiviral activity, “–” no antiviral activity; * antiviral activity against other influenza 
A(H1N1)pdm09 strains listed in Table 16, except A/Helsinki/552/2013 (H1N1pdm09) strain that is 
insensitive to MK-2206 treatment; ** no reduction of virus titers; n.a., not available.  
 
To examine whether these host factors are essential for other virus infections, the 
same inhibitors were tested against four enveloped RNA viruses (BUNV, MeV, SINV, 
SFV), two enveloped DNA viruses (HSV-1 and VACV) and one non-enveloped RNA 
virus (Echo6) (Table 19). Of these, SFV is similar to influenza virus in that it is known 
to utilize endocytosis to enter the cell. It was found that obatoclax efficiently attenuated 
infections and reduced virus production of BUNV, SINV and Echo6, whereas SaliPhe 
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suppressed infection of BUNV and SINV. Obatoclax and SaliPhe were able to rescue 
SFV-infected cells, however no reduction in the numbers of infectious virus particles 
was observed. Moreover, gemcitabine suppressed HSV-1, SINV, SFV and Echo6 virus 
infections. 
In summary, SaliPhe and obatoclax exerted antiviral activity against a broad range 
of influenza and some other RNA viruses. Obatoclax was toxic to cells during 
prolonged incubation periods and, for this reason, was excluded from further studies. 
Thus, subsequent studies focused on SaliPhe as the most potential antiviral agent. 
However, it will be interesting to test the antiviral potential of another selective 
inhibitor of Mcl-1, maronopyrrole A (maritoclax), which has higher specificity and 
better pharmacological properties in comparison to obatoclax (Doi et al, 2012). 
4.5. Development of resistance (unpublished) 
The increasing clinical use of licensed antivirals has been associated with the 
global emergence of amantadine- and/or oseltamivir-resistant influenza strains (Hayden 
& de Jong, 2011; Zhou et al, 2013). Resistance results from both antigenic drift and 
antigenic shift events specific for influenza viruses. Therefore, current prevention 
options for influenza infections are limited and there is a need for developing next-
generation antiviral agents. Although, it was emphasized above that targeting host 
factors essential for virus biology would be associated with a decreased likelihood of 
resistance emergence, examples of virus resistance to potential host-directed antivirals 
have been described in the literature (Qing et al, 2010; Triana-Baltzer et al, 2009). 
The next experiment assessed whether continued inhibition of cellular v-ATPase 
by SaliPhe could lead to the emergence of resistant influenza virus variants by 
conducting a serial-passage experiment. During passaging the concentration of SaliPhe 
was gradually increased. It is argued that this strategy does provide enough time for 
virus resistance to emerge. A total of 15 passages were performed and the virus titer 
determined after each passage. The results showed that the virus titer in the presence of 
SaliPhe (0.35 µM, passage #8) decreased, and was not restored in further passages 
(Figure 6). These results confirm the hypothesis that the influenza A/Helsinki/P14/2009 
strain cannot efficiently adapt to selective pressure associated with the reduction of v-
ATPase activity. Thus, it is concluded that SaliPhe is a promising antiviral agent 
exhibiting a high-barrier to case resistant virus variants. 
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Figure 6. Influenza A/Helsinki/P14/2009 virus titers from the serial-passage experiment on 
NCI-H1666 cells. 
 
4.6. Optimization of SaliPhe clinical utility (III) 
SaliPhe is a small-molecule inhibitor of v-ATPase, a potential target for antitumor 
chemotherapy (Lebreton et al, 2008). Moreover, on particle-induced osteolysis in vivo 
SaliPhe was shown to inhibit bone destruction and suppress inflammatory response (Qin 
et al, 2012). In addition, SaliPhe is a potential antiviral drug. It has been shown 
previously that SaliPhe increases the survival rates of mice infected with lethal doses of 
a mouse-adapted influenza strain (Müller et al, 2011). However, SaliPhe has a low 
water solubility and high toxicity that are major bottlenecks for the evaluation of this 
compound in the clinic (Müller et al, 2011).  
In an attempt to increase the solubility and bioavailability of SaliPhe and to 
reduce side-effects, it was decided to evaluate the PSi nanoparticle-based delivery 
system that encompasses several advantageous properties for drug delivery. It has been 
shown that PSi-based materials increase dissolution of otherwise poorly water-soluble 
drugs loaded within its mesopores (Bimbo et al, 2011; Salonen et al, 2008). SaliPhe was 
loaded into thermally hydrocarbonized porous silicon (THCPSi) nanoparticles with a 
loading degree 2.88±0.11 wt% and then the drug releasing properties of SaliPhe-loaded 
THCPSi nanoparticles were investigated. It was observed that at pH 7.4 THCPSi 
nanoparticles released approximately 30% of the loaded SaliPhe during the first 15 
minutes (III, fig. 3). In contrast, the pure form of SaliPhe could achieve only a 5% 
dissolution within the same time period. Importantly, the THCPSi nanoparticles allowed 
the delivery of SaliPhe in the absence of DMSO, and they increased the drug dissolution 
rates in comparison to the pure drug. 
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The SaliPhe-loaded THCPSi nanoparticles were further investigated for their 
ability to inhibit the influenza A/PR8-NS116-GFP virus infection in vitro. It was 
observed that SaliPhe-loaded THCPSi nanoparticles like SaliPhe dissolved in DMSO 
efficiently inhibited influenza virus-mediated GFP expression and reduced virus titers 
by more than two orders of magnitude (III, fig. 5 and fig. 7). In addition, SaliPhe-
loaded THCPSi nanoparticles exerted less cytotoxic effects than SaliPhe dissolved in 
DMSO (III, fig. 4 and fig. 5). Thus, the therapeutic window of SaliPhe-loaded THCPSi 
nanoparticles was wider in comparison with SaliPhe dissolved in DMSO. 
This data provides the first proof-of-principle of the potential of THCPSi 
nanoparticles to delivery antiviral agent to virus-infected cells and to inhibit the 
infection. Optimization of administration routes, such as inhalation or intravenous 
injection, is currently envisioned, and further preclinical evaluation is warranted for the 
development of PSi nanoparticles-based delivery systems as a potential platform for 
targeted delivery of antiviral compounds in vivo. 
56 
 
5. FUTURE DIRECTIONS 
Currently, the usage of licensed anti-influenza drugs is limited due to the globally 
circulating drug-resistant influenza strains. It is essential to develop of new potential 
antivirals targeting cellular host factors or components of signaling pathways in order to 
control and treat future influenza virus epidemics and pandemics. Host-directed 
antiviral agents represent a very attractive approach because the likelihood of resistance 
emergence is very low and host-directed antivirals might possess broad-spectrum 
antiviral properties.  
The drug screening described in Study I focused on the cellular requirements for 
virus entry, uncoating, nuclear import, and viral RNA transcription/translation. Another 
screen was performed against wild type influenza A and B viruses in order to identify 
host factors involved in other stages of influenza virus in A549 cells. The screen 
revealed compounds identified in the previous screen (I) and a number of potential 
antiviral-agents (unpublished). The hit list and EC50 values are presented in Table 20. 
Additionally, their antiviral activity was tested against avian influenza A (H5N1 and 
H7N9) strains. It is clear that further investigation of their mechanism of action and 
their antiviral efficacy in vivo is needed. 
Table 20. Identified compounds and their antiviral activity against influenza infection. 
Name Target EC50 (µM)* 
A(H1N1)
a
 A (H5N1)
b
 A(H7N9)
c
 B
d
 
Flavopiridol 
(Alvocidib) 
CDK 0.60 0.34 
 
0.47 0.50 
SNS-032  
(BMS-387032) 
CDK 0.32 0.38 
 
1.00 0.50 
Dinaciclib 
(SCH727965) 
CDK 0.12 0.04 
 
0.04 0.04 
DCC-2036 
(Rebastinib) 
Abl 0.04 – 
 
0.04 2.50 
PIK-75 PI3K 0.08 0.08 – 0.13 
Homoharring-
tonine 
60S ribosome – – 
 
– 0.12 
* values obtained on A549 cells;  “–” no antiviral activity;  
a A/WSN/33; b A/Chicken/Nigeria/BA211/2006; c A/Anhui/01/2013; d B/Shandong/7/97. 
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6. CONCLUSIONS 
A screening approach was developed to identify druggable host factors involved 
in influenza virus replication and it was efficiently used to reveal cellular Mcl-1, v-
ATPase, ribonucleotide reductase, Akt kinase and Bcl-xL. The detailed molecular 
mechanisms of action of potential antiviral agents, such as obatoclax, SaliPhe, 
gemcitabine, MK-2206 and ABT-263, targeting these host proteins, have been 
elucidated. These potential antiviral agents demonstrated a broad spectrum of antiviral 
activities in vitro. However, ABT-263, an inhibitor of Bcl-2 family proteins, was 
ineffective in vivo. SaliPhe showed the greatest as an antiviral agent with activity 
against a broad range of influenza A and B viruses and some other RNA viruses in vitro 
and against a mouse adapted influenza strain in vivo. In order to overcome a low water 
solubility and high toxicity of SaliPhe, its bioavailability was improved using a porous 
silicon particle-based delivery system for use in future clinical trials. The results 
presented in this thesis expand the understanding of virus-host interactions, and provide 
a novel perspective for ways to adopt a rational approach in the discovery of new 
antiviral agents. 
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